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ABSTRACT

PANcreatic-DERived Factor (PANDER), or FAM3B, is a 235-amino acid protein strongly
expressed within and secreted from the endocrine pancreas. Research surrounding PANDER has
revealed a large role for the protein in maintaining glucose homeostasis, as evidenced by
several Ad-PANDER overexpressing murine models, our lab’s pancreas-specific PANDER
transgenic overexpressor, and most recently our mixed genetic C57/129J PANDER knockout
(PANKO) mouse. However, PANDER’s overall role in glycemic regulation and glucose
homeostasis has yet to be studied in a purebred C57BL/6J PANDER knockout model. Here we
present the first phenotypic characterization of our global PANDER knockout mouse on a
C57BL/6J background (PANKO-C57) where we examined metabolics through glucose/insulin
tolerance testing, fasting glycemia, and body weights, the concentrations of hormonal analytes
along with lipids and corticosterones, and full elucidation of hepatic insulin signaling through the
insulin signaling cascade. Overall, the PANKO-C57 mice exhibited increased body weights with
enhanced glucose tolerance and lower fasting glycemia, similar peripheral insulin sensitivities,
increased hepatic lipidemia, and enhanced hepatic insulin signaling at critical insulin signaling
molecules. Taken together, the PANKO-C57 demonstrates that the disruption of PANDER results
in selectively enhanced hepatic insulin signaling yet with increased lipidemia and overall body
weight. These findings reveal a novel role for PANDER in differentially controlling lipogenesis
and hepatic glucose production that may selectively impact overall glycemic control and
potentially

facilitate

the

onset

and/or

vi

progression

of

type

2

diabetes.

CHAPTER ONE: INTRODUCTION

Typical Glycemic Regulation
Glycemic regulation, or the maintenance of glucose homeostasis within the body, is a
process that is tightly regulated by not only numerous hormones but also by many organs
including the brain, liver, pancreas, skeletal muscle, and even the intestines [1-4]. The brain, in
particular, relies on glucose as its main source of energy and oxidation to function and conduct
processes through all neuronal tissue. In conditions where glucose in the blood is low, or
hypoglycemia, the brain’s functions become abnormal and can ultimately lead to death [2].
However, by working cooperatively with the liver, pancreas, and skeletal muscle, the brain is
allowed to operate properly while still allowing for optimal glucose homeostasis through glucose
production and subsequent utilization [1-4]. It is most important that the maintenance of
glycemia is tightly regulated especially in times of fasting and fed when blood sugar
concentrations fluctuate so greatly. The balance of various hormones from the brain, gut, and
pancreas secreted at optimal times in response to fluctuating blood glucose allow for maximal
functioning of glycemic regulation and glucose homeostasis.

Fed State Glycemic Regulation
The balance between glucose entrance into and departure from the bloodstream is at
the forefront of importance in maintaining proper glucose homeostasis. The primary source of
circulating glucose is through ingestion of a meal (fed state/postprandial) and subsequent
gastric emptying by digestive enzymes [1, 4, 5]. The regulation of postprandial circulating
glucose appearance is due, in large part, to the action of 2 hormones referred to as incretins1

GIP (Glucose-dependent Insulinotropic Polypeptide, formerly Gastric Inhibitory Polypeptide) and
GLP-1 (Glucagon-Like Peptide 1). GIP and GLP-1 are secreted from intestinal K-cells and L-cells,
respectively, in response to oral ingestion of a meal that is rich in carbohydrates and/or fats [1,
4, 5]. Their mechanisms of action differ, however, in that although they both stimulate the
biosynthesis and release of insulin from pancreatic β-cells, GLP-1 slows gastric emptying to
properly correlate glucose appearance with timely release of insulin and prevents glucagon
secretion whereas GIP works primarily in adipose tissue for fat metabolism [4, 5, 25]. Their
levels under normal glycemic conditions differ, too, in that because GLP-1 is more
physiologically relevant to humans, it fluctuates from levels being high postprandially and much
lower when fasting [1]. Taken together, GIP and GLP-1 work cooperatively with insulin and
glucagon to speed glucose disappearance to surrounding tissues and organs after oral nutrient
uptake. Additionally, amylin, a neuroendocrine hormone secreted by pancreatic β-cells with
insulin, works in concert with insulin to increase glucose disappearance and slow gastric
emptying to prevent spikes in blood glucose [8]. Perhaps more importantly, amylin suppresses
glucagon, a hormone secreted by pancreatic α-cells (and inhibited by insulin) in times of fasting
when plasma glucose levels are low to enhance hepatic glucose production (HGP) [1, 8, 9]. By
suppressing the action of glucagon postprandially, amylin chiefly regulates the appearance of
endogenous glucose from the liver in addition to exogenous glucose from meal intake [1]
(Summarized in Figure 1). Insulin, a potent anabolic hormone, also allows for glucose utilization
through the process of glycolysis [2, 6]. When insulin is released from pancreatic β-cells
through GLP-1 and GIP stimulation, there is a consequential rise in plasma insulin levels,
triggering the uptake of glucose into cells for oxidation.

When glucose is transported into

muscle, liver, and fat cells through glucose transporters, it is shuttled through the oxidative
process of glycolysis and The Citric Acid (TCA) Cycle to yield ATP for cellular energy [1, 4, 5, 8].
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Figure 1: Fed State Network of Interactions in Normal Glycemic Regulation. Illustration
representing the normal regulation of glycemia in the fed state, beginning with nutrient stimulation from
the brain, stimulating the simultaneous release of amylin with insulin stimulated by GLP-1 and GIP.
Amylin and GLP-1 slow gastric emptying and GLP-1 works with insulin to inhibit glucagon secretion in
turn decreasing glucose output while plasma glucose and consequent glucose disappearance increases
(adapted from Aronoff et al., 2004 [1])

Fasting State Glycemic Regulation
On the other hand, under fasting conditions when circulating glucose is scarce, the liver
is utilized to upregulate glucose output into circulation through two discrete mechanisms. HGP
is accomplished in the liver by breaking down glycogen through glycogenolysis and also via de-

novo synthesis from amino acids and other carbon derivatives through gluconeogenesis [1, 2,
6]. First, glucose is stored within the liver (and muscle) as glycogen, a highly branched
polymerized molecule with an α-(1, 6) linkage every 10 glucose residues that carries an average
of 4 kcal of energy per gram of tissue [1, 2]. Under the control of the hormone glucagon (when
plasma insulin levels are low) and in fasting conditions up to 8-12 hours, glycogenolysis is the
primary source of glucose output from the liver [1, 9]. The hydrolysis of glycogen is initiated
with the cleavage of a single glucose-1-phosphate molecule off of the branched polymer by
3

glycogen phosphorylase, activated by the binding of glucagon to its putative receptor on the
plasma membrane. Then, the glucose-1-phosphate molecule is converted to glucose-6phosphate, a gluconeogenic intermediate, to be acted on by glucose-6-phosphatase (G6Pase),
where it is then converted to glucose and able to be transported out of the cell [1, 2]. After
approximately 8-12 hours of prolonged fasting, the main source of hepatic glucose output
switches from glycogenolysis to gluconeogenesis where amino acids, free fatty acids, and other
fuel sources are used to synthesize glucose, still under the control of glucagon [2, 25]. Through
the conversion of these fuel sources into pyruvate, oxaloacetate can then be formed and
converted into phosphoenolpyruvate, the first gluconeogenic intermediate which will undergo
steps that use ATP to form glucose. Insulin is another dominant regulator of glycogenolysis and
gluconeogenesis in that the presence of insulin, signaling that glucose is in abundance in the
body/plasma, both gluconeogenesis and glycogenolysis are inhibited [1, 2, 6]. In insulin
sensitive individuals, when the release of insulin is triggered and binding of insulin to the insulin
receptor on the hepatocyte membrane is accomplished, glucose is drawn into the cell to form
glycogen and the formation of gluconeogenic precursors is inhibited [6]. Together, these 3
sources of circulating glucose allow for continued euglycemia in the fasting state when all other
conditions inside the body are normal.

Insulin Signaling
The intricacies involved in the molecular aspect of insulin signaling is complex, beginning
with the binding of insulin to its receptor at the cell membrane and activating a cascade of
effects. When the release of insulin by the pancreatic β-cell is stimulated by an increase in
blood glucose or by incretins, it signals the skeletal muscle and liver to 1) stimulate the uptake
of glucose and 2) promote the formation of glycogen (glycogenesis) and halt gluconeogenesis
by inhibiting the action of glucagon specifically on the liver [1]. Insulin does this by binding to
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its tetrameric tyrosine-kinase Insulin Receptor (IR) where it becomes autophosphorylated,
stimulating the phosphorylation of members of the Insulin Receptor Substrate (IRS) subfamily
[6, 25]. Specifically, IRS-1 will physically interact with the p85 domain of Phosphatidylinositol-3’Kinase (PI3K) immediately after it becomes tyrosine phosphorylated by IR, which then activates
many downstream proteins, perhaps most importantly, Akt or Protein Kinase B (PKB) [6, 7, 22,
23]. The cascade of phosphorylation events through Akt allows for the exocytosis of Glucose
Transporter (GLUT2 in the liver, GLUT4 in muscle and adipose tissue) from vessicles to
subsequent translocation to the cell surface, allowing for the uptake of glucose into the cell [2,
6]. Simultaneously, Akt will phosphorylate Glycogen Synthase Kinase-3 (GSK3), effectively
inactivating it and decreasing the rate of phosphorylation of Glycogen Synthase (GS), allowing
for the synthesis of glycogen [6, 25]. Lastly, the binding of insulin to IR stimulates fatty-acid
synthesis rather than degradation by activating various transcription factors such as Sterol
Regulatory Element-Binding Protein 1 (SREBP-1) and enzymes including Acetyl CoA Carboxylase
(ACC) and Fatty Acid Synthase (FAS) [3, 6]. Another protein important in hepatic insulin
signaling is cAMP-Responsive Element Binding Protein (CREB) as it further controls hepatic
glucose production (Summarized in Figure 2) [52, 54]. CREB is most important in the fasted
state where the cyclic AMP (cAMP) family of proteins become activated by the binding of
glucagon to the glucagon receptor and ultimately upregulate the phosphorylation of CREB, a
transcription factor that activates the transcription of gluconeogenic enzyme G6Pase and
Phosphoenolpyruvate Carboxykinase (PEPCK) [54, 55, 56, 57]. Insulin will also inhibit the
transcription of certain gluconeogenic enzymes, mainly PEPCK and G6Pase by nuclear exclusion
of the transcription factor Forkhead Box Protein O1 (FOXO1) [25, 26]. In conclusion, insulin
sensitivity at the peripheral (muscle) and hepatic level allow for proper insulin signaling
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resulting in glucose uptake through glucose transporters, fatty-acid synthesis through SREBP-1,
and gluconeogenic enzyme suppression by FOXO1.

Figure 2: Insulin Signaling Network in Insulin Sensitive Individuals. Insulin signaling cascade,
beginning with the binding of insulin to the Insulin Receptor at the plasma membrane, triggers a
phosphorylation cascade that ultimately results in upregulation of glycogen synthesis, inhibition of
gluconeogenesis, and upregulation of lipid synthesis along with GLUT translocation to plasma membrane
and glucose uptake (adapted from Saltiel et al., 2001 [6]).

Type 2 Diabetes (T2D)
As of 2012, globally, diabetes affected 371 million people, 50% of which continued to be
undiagnosed [10]. What’s more, the number of people across the world with diabetes is
expected to rise to almost 440 million people by the year 2030. [11]. Here in the United States,
according to the Center for Disease Control and Prevention (CDC), an estimated 25.8 million
people, or 8.3% of the United States, has diabetes, 7 million of which were undiagnosed [12,
15]. Of all of the people with diabetes in the United States and across the world, 90-95% of
them have type 2 diabetes [12, 13, 14]. Type 2 diabetes accounts for approximately 12-15% of
all healthcare expenditures across the globe and has been a causative factor (if not the only
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causative factor) in almost 250,000 US deaths [12, 14]. The global epidemic that is type 2
diabetes threatens to substantially worsen within the next 2 decades making the study of and
prevention of this multi-faceted disease at the forefront of scientific interest today [13].
Type 2 diabetes, also known as “non-insulin dependent diabetes mellitus” or “adultonset diabetes,” is a complex disease defined by insulin resistance/impaired insulin sensitivity
due to impaired β-cell function and failure of target tissues to respond to secreted insulin [12,
14]. These defects result in constant hyperglycemia because of impaired glucose tolerance
(IGT) and glucose utilization, increase in hepatic glucose production, dysregulation of insulin
signaling, and an increase in circulating free fatty acids [13, 14]. Mechanistically, insulin
resistance, considered a central problem in T2D, occurs beyond the Insulin Receptor (IR) in
cells, as tyrosine phosphorylation of IR in type 2 diabetic patients is unaffected in skeletal
muscle, the main site of glucose disposal [14, 16]. Instead, insulin-induced phosphorylation of
IRS-1 and PI3-K, immediately downstream from IR, have been shown to be significantly
reduced in type 2 diabetic patients with no change in either protein levels. Further, the same
trend of decreased phosphorylation with no change in protein level was also characterized in
regards to Akt in type 2 diabetic patient samples [16, 20]. Together, these indicate that defects
exist in transmitting the phsophorylation signal when insulin binds to IR in the progression of
type 2 diabetes [14, 16, 20, 21]. These abnormalities in insulin signaling ultimately result in a
reduction of glucose transporter translocation to the cell surface, leading to a subsequent
decrease in glucose uptake by the cell and plasma hyperglycemia [14, 19, 20]. Consequently,
the worsening hyperglycemia (among other things) leads to an increased need for insulin
production and secretion from the pancreatic β-cell. This sets in motion a vicious cycle of
hyperglycemia and hyperinsulinemia, 2 well known type 2 diabetic hallmarks. These are in
addition to the hyperlipidemia that is also present in T2D. However, over time, the β-cell can no
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longer compensate for the increase in blood glucose levels and insulin secretion eventually
decreases significantly along with an overall decrease in β-cell mass and increase in β-cell
apoptosis [12, 14, 17, 18, 24].
The liver, another significant factor in the pathogenesis of type 2 diabetes, controls
glycogenolysis and gluconeogenesis, both being the main source of glucose output in fasted
conditions. Glucose homeostasis is significantly skewed when insulin signaling is disrupted
specifically within the liver, as it results in a failure to suppress HGP and worsened glucose
intolerance, both found in type 2 diabetes [25, 27, 28]. In fact, excessive HGP from the liver
positively correlates with fasting hyperglycemia and HGP rates consistently increase with
increasing hyperglycemia through T2D disease progression [28-31]. Insulin’s direct effect on
HGP suppression, through binding to its putative receptor on the hepatocyte membrane, is
severely disrupted in insulin resistant states. Rising plasma hyperinsulinemia due to hepatic
insulin resistance further contributes to continued glucose output by the liver and
compentsatory hyperglycemia [6, 28, 29, 30]. When insulin does not bind specifically to its
hepatic IR because of decreased sensitivity, phosphorylation of IRS-1, PI3-K, and Akt does not
occur, ultimately resulting in GSK-3 activation, glycogenolysis will occur, and FOXO1 will be
allowed to enter the nucleus to transcribe gluconeogenic enzymes [6, 25, 26]. Furthermore,
Michael et al. discovered that when hepatic insulin resistance is modeled where insulin is made
unable to bind to hepatic IR, mRNA expression of both G6Pase and PEPCK are significantly
increased, indicating that HGP is highly upregulated [27]. The same group also reported that
this insulin resistance, studied in liver-specific IR knockout mice, promotes overall
hyperinsulinemia by simultaneously decreasing insulin clearance while also increasing insulin
secretion [27].
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Discovery of PANcreatic-DERived Factor (PANDER)
PANcreatic-DERived Factor (PANDER) was initally discovered in 2002 during a screen for
new cytokines using an Ostensible Recognition of Folds (ORF) algorithm. This algorithm uses
comparisons, such as known cytokines to an unknown sequence, to determine a protein’s
predicted secondary structure [32, 38]. Using a

database of known sequences, the ORF

algorithm uses sequence alignment of repetitive and non-repetitive sequences to establish
proteins that are homologous in their secondary structures [32, 38]. That is, instead of using a
protein’s amino acid residue sequence, GORII parameters are used to calculate a protein’s
secondary structure string which is then used in sequence alignment [32, 34, 38]. In the search
that uncovered PANDER, secondary structure probes from short chain cytokines like interleukin
(IL)-2, -3, -4, growth hormone, etc. were utilized and the NCBI GenPept Database was used as
the known library [34]. The 4-helix bundle secondary structure with up-up-down-down topology
of these cytokines used as probes has remained highly conserved throughout the course of
evolution [33, 34]. In addition to the 4-helix bundle and unique topology, 2 disulfide bridges
linking the 4 helices at conserved cysteine residues are also signature to these cytokines,
allowing them to be excellent candidates for structure-based studies such as the ORF algorithm
[34]. A novel family of proteins entitled family with sequence similarity 3 (FAM3) was
discovered from the ORF search with 4 putative gene members- FAM3A being the first
discovered, followed by FAM3B, FAM3C, and FAM3D [34, 35, 36, 37]. All 4 family members
consist of 224-235 amino acids and share 31.6-53.3% homology between, but no homology to
known cytokines besides their predicted secondary structures, perhaps indicating the discovery
of a novel cytokine subfamily [34, 39]. FAM3B, the second of the 4 genes discovered, is the
longest FAM3 family member at 235 amino acids long and was later renamed “PANDER”
because of its robust mRNA expression within the endocrine pancreas determined by northern
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blot [34, 44]. PANDER mRNA is also expressed to lesser extents within the small intestine and
prostate [34].

Newly Discovered Structure of PANDER
In early 2013, the three-dimensional crystal structure of murine PANDER was elucidated
using sulfur singular anomalous dispersion (S-SAD) and X-ray data [40]. Johansson et al.
showed using two different constructs of murine recombinant PANDER, unglycosylated (S)E30
PANDER and a truncated S46 PANDER, that 1) PANDER is, in fact, not a protein made of all αhelices and 2) its protein structure displays a globular β-β-α fold made of 2 anti-parallel βsheets and a single layer of 3 short α-helices (Figure 3) [40]. Composed of 9 strands in total,
the first β-sheet contains 4 strands, leaving 5 strands in the second β-sheet, creating a
completely hydrophobic core within the protein structure [40]. The N-terminal tail of PANDER
contains the disulfide bridges between cysteine residues that was initially believed to be at
positions 63-69 and at positions 91-229 in the previous 4-helix model, but is in actuality at
positions 63-91 and 69-229 [40, 43]. PANDER’s N-terminus also contains the signal peptide in
the first 30 amino acid residues, followed by the next 29 residues being hidden within the
protein itself though they, along with the structural integrity of the β-β-α fold are essential to
PANDER’s overall functionality [40]. These new findings further contradict initial structurefunction studies of PANDER which revealed that truncation of the entire N-terminus had no
effect on PANDER function and action [43]. PANDER’s new structure also revealed a highly
conserved 4 water molecule-filled cavity that rests between the 2 β-sheets and has been shown
to contribute to relative thermal stability of PANDER overall, contrary to evidence that such
internal protein packing substantially destabilizes proteins [40, 42].
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Figure 3: Secondary and Crystal Structure of PANDER. This figure illustrates the ribbon secondary
structure (Left) of FAM3B (PANDER) depicting β-sheets in light blue with α-helices in purple (enhanced
from Protein DataBase: 2YOQ) and the globular crystal structure form (Right) of the FAM3B protein (also
adapted from PDB: 2YOQ) [40].

Perhaps the most telling feature of PANDER is that it bears no resemblance to not only
other cytokines that were utilized in its discovery nor to its previously hypothesized 4-helix
bundle structure, but also to any known protein. In fact, the protein that possesses the highest
similarity to PANDER was Top7, a novel artificial protein that was specifically created to assess
the boundaries of realizable proteins structures [40, 41]. Given that there are currently no
known biological proteins that remotely share the same structure as PANDER, this is indication
that PANDER could potentially represent a brand new structural class of signaling molecules
with unique functions [40, 41].

Genomic Structure of PANDER
Initial characterization of PANDER in 2002 revealed that, genomically, human PANDER is
present on chromosome 21q22 with a total of 8 exons over a 40 kb region and murine PANDER
is located on chromosome 16B5-C4 [34, 45]. A typical signal peptide was also discovered both
in the murine and human form of PANDER on the N-terminus with a hydrophobic leader
sequence, indicating targeting to the endoplasmic reticulum (ER) for secretion from the cell [34,
11

52]. This processing of PANDER gives rise to a 23 kDa secreted PANDER product as opposed to
the full-length 235 amino acid protein at 26 kDa, both detected in cell lysate and media from
hepatocytes and β-TC3 cells infected with PANDER [34, 44, 52, 67]. Using the 5’- RNA Ligase
Mediated-Rapid Amplification of cDNA Ends (RLM RACE) method, the PANDER transcriptional
start site in insulin-producing pancreatic β-TC3 cells was identified 520 bp upstream from the
translational start codon [45, 63]. Within the 5’ flanking region of the PANDER gene at positions
-99 and -48 uptream of the transcriptional start site are 2 TATA boxes and 3 A-box and E-box
elements each from -335 to +491 bp, indicating a potential responsiveness of the PANDER
promoter to glucose, much like that of the insulin promoter [45, 48]. Additionally, hepatocyte
nuclear factor (HNF) 1 and 4, octamer binding protein-1 (Oct-1), and signal transducer and
activator of transcription (STAT) 3, 5, and 6 binding sites were identified, indicating isletspecificity [45]. HNF-1 and HNF-4, though normal in the pancreas, regulate hepatocyte
transcription and indicate expression within liver-derived cell lines as well, verified by an
increase in PANDER promoter activity in BNL-CL2 liver-derived cell lines [45, 62]. In summary,
the 5’ untranslated region (5’ UTR) of the PANDER gene contains not only the PANDER
promoter and transcriptional start site, but all of the putative transcriptional factor binding sites
that potentially give PANDER its tissue-specificity and nutrient responsiveness [34, 45, 49].

Regulation of PANDER Transcription
Following the lead of other various islet-specific proteins like insulin and glucagon
mentioned previously, dominant control of their expression is exhibited at the transcriptional
level by promoter elements and nutrient responsiveness [45, 46, 47]. This led to the further
characterization of the regulatory regions and the islet-specific transcriptional elements that
control PANDER expression at the transcriptional level.
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First, Burkhardt et al. reported that the minimal element required for maximal promoter
activity and PANDER gene expression happens to be in the +200/+491 region where all 3 E-box
elements and a single A-box lie [45, 49]. Further, given that the PANDER promoter contains
several E- and A-box elements and therefore could potentially be stimulated by glucose, glucose
stimulation experiments were performed using various constructs of the PANDER promoter
containing a number of those elements [45]. It was reported that the PANDER promoter was
significantly upregulated by glucose in a dose-dependent manner and that treatment of β-TC3
cells with 22 mM D-glucose had the biggest increase in promoter activity when using luciferase
plasmids under the control of the PANDER promoter [45]. This significant response of the
promoter to glucose was also observed in murine pancreatic islets that were transfected with
luciferase/PANDER plasmids but not in α-TC3 cells that secrete glucagon, indicating cell-type
and nutrient specific expression of PANDER [45, 52]. The mechanism of the PANDER promoter’s
glucose responsiveness was found to be due to CREB-dependent pathway involving Ca2+, and
either PKA or PKC where CREB phosphorylation was increased as well as PANDER gene
expression in response to glucose [52, 65].
Cell-specificity was further conformed when cis elements within the promoter, A-boxes
specifically, proved to be essential for binding an important transcription factor in pancreatic
development, Pancreatic/Duodenal Homeobox-1 (PDX-1) [49, 50, 52]. Using chromatin
immunoprecipitation (ChIP) and electromobility shift assay (EMSA), Burkhardt et al. showed
that PDX-1 binds to all 3 of the A-boxes in the PANDER promoter in the -338 to +491 region
and site directed mutagenesis of the 2 A-boxes in the -100 to +491 region completely
deteriorated PANDER promoter activity [49, 52]. The same 2 A-boxes proved to be critical in
the PANDER promoter’s glucose responsiveness as their combined mutagenesis markedly
reduced promoter activity [49, 52]. Additionally, 2 more β-cell specific transcription factors, V-
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maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) and β-cell E box
Transactivator 2/NeuroD (BETA2/NeuroD) significantly upregulated activity of the PANDER
promoter when combined with PDX-1, though PDX-1 alone had the greatest effect [49, 52, 64].
As a whole, PANDER transcription is regulated by β-cell specific transcription factors that bind to
elements within the PANDER promoter and enhance promoter response to glucose stmulation,
among other nutrients.

Regulation of PANDER Secretion
Just as PANDER transcription was enhanced by glucose, PANDER secretion has also
been shown to be upregulated by glucose, for one. PANDER has been reported to co-localize
with insulin in secretory granules of β-cells as shown by immunogold-labeling electron
microscopy, and not only did glucose induce PANDER mRNA and protein expression in β-cells
and islets, but it also increased PANDER secretion dose-dependently from β-cells almost 3-fold
[52, 65, 66, 68]. The same effect was observed when PANDER was overexpressed in murine
islets [66]. Interestingly, PANDER secretion from β-cells positively correlated with glucosestimulated insulin secretion (GSIS) from the same cells, indicating the possibility that PANDER is
likely co-secreted with insulin [66].
PANDER was also observed to be secreted from pancreatic α-cells, though secretion was
not upregulated by increasing to decreasing glucose stimulation [52, 66, 69]. Carnegie et al.
first reported that PANDER was present in pancreatic α-TC1-6 cells in granular cytoplasmic
compartments and does not co-localize with glucagon [52, 69]. However, when stimulated with
L-Arginine, the most robust known stimulator of glucagon secretion, PANDER secretion
increased from α-TC1-6 cells significantly at up to 20 mM treatment in addition to a significant
increase in glucagon secretion [52, 69, 70, 71]. What’s more, when treated with low
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concentrations of insulin (17 nM) alone or in combination with L-Arginine, PANDER secretion
from α-TC1-6 cells was significantly increased (moreso when treated with insulin alone), while
still allowing for insulin-induced glucagon suppression [52, 69]. The mechanism for the
unexpected upregulation of PANDER secretion from α-TC1-6 cells in response to insulin was
reported to be attributed to the PI3K-Akt node of insulin signaling [69]. In general, PANDER is
present in and secreted from pancreatic islets, α-cells, and β-cells in response to a variety of
nutrient stimuli including glucose in β-cells and L-Arginine and insulin in α-cells, indicating a
potential role for PANDER in glucose homeostasis functioning in glucoregulatory mechanisms
[52].

Summary of PANDER Animal Models
Characterization of PANDER in-vivo has only recently begun within the past 3 years with
numerous PANDER animal models being created. Not only are there PANDER knockout models,
but also siRNA PANDER knockdown models, adenovirus-PANDER overexpressing models, and a
recently characterized PANDER transgenic model to contribute to the characterization of
PANDER’s biological role in-vivo.

Hepatic Ad-PANDER Overexpressor and siRNA Knockdown
Li et al. developed a hepatic PANDER overexpressor by injecting adenoviral-PANDER
(ad-PANDER) into the tail of C57BL/6 mice targeted for the liver [51, 62]. This hepatic-specific
PANDER overexpression increased significantly increased hepatic steatosis with an increase in
triglycerides within the serum and upregulation in both mRNA and protein expression of lipid
metabolism genes including SREBP-1, FAS, and peroxisome proliferator-activated receptor γ
(PPARγ) [51, 52, 62]. In addition, plasma insulin levels were increased with disruption of
phosphorylation of proteins in the hepatic insulin signaling cascade, specifically Akt, 5’
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adenosine monophosphate-activated protein kinase (AMPK), and the transcription factor
FOXO1, though unphosphorylated FOXO1 expression was the most markedly increased [51,
62]. Small-interfering RNA (siRNA) knockdown of hepatic PANDER was reported by the same
group to reverse all of the above affects, but in db/db mice, a mouse strain used to model type
2 diabetes, not C57BL/6 mice [51, 52, 53]. Hepatic PANDER silencing also significantly reduced
blood glucose levels and improved insulin resistance by decreasing expression of gluconeogenic
enzymes and increasing phosphorylation of both Akt and AMPK while reducing the expression of
FOXO1 [51, 52, 62]. Taken together, these ad-PANDER and siRNA knockdown models suggest
that PANDER induces hepatic lipogenesis and insulin resistance primarily through a FOXO1
dependent pathway where PANDER decreases the phosphorylation of key insulin signaling
proteins to aid in the increase in FOXO1 [51, 62].

Ad-PANDER Overexpressor
Wilson et al. also created a serum PANDER overexpressor using adenoviral gene delivery
into the tail vein of male C57BL/6 mice [52, 54, 62]. This ad-PANDER model presented with
increased fasting blood glucose levels and the compensatory hyperinsulinemia due primarily to
elevated levels of corticosterone (murine glucocorticoids) and not glucagon, glycogen, or any
other factor [52, 54]. Corticosterones/glucocorticoids have been shown to be present in higher
concentrations in type 2 diabetic obese models and are reported to increase blood glucose
levels through increasing gluconeogenesis and perpetuate insulin resistance in vivo [52, 54, 58,
59]. Ad-PANDER mice were also shown to be glucose intolerant during a glucose tolerance test
(GTT), the result of the fasting hyperglycemia, as the mice were peripherally insulin sensitive
[54, 62]. Further, PANDER overexpression in these C57BL/6 mice after an overnight fast and
after being refed for 4-hours following an overnight fast resulted in an increase in mRNA
expression of G6Pase and PEPCK, though only significant without being refed [52, 54, 62].
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There was also no observed effect on the phosphorylation of Akt or GSK3 levels in the adPANDER mice, with the ad-PANDER mice revealing a decrease in liver triglycerides, contrary to
the previously mentioned ad-PANDER murine model [51, 54]. In all, this specific ad-PANDER
model suggests a role for PANDER as a causative agent of hyperglycemia in glucose
homeostasis in the fasting state, by upregulating HGP through gluconeogenesis and increasing
corticosterone levels [52, 54].

PANDER Transgenic Overexpressor
A PANDER transgenic (PANTG) mouse was created to specifically overexpress PANDER
in the pancreas, specifically in the islets, using a portion of the PDX-1 promoter in B6SJLF1/J
mice [50, 80, 81, 82, 96]. These mice initially presented with decreased β-cell mass and glucose
intolerance on HFD, mimicking that of a type 2 diabetic model [80]. Further characterization of
these PANTG mice using hyperinsulinemic-euglycemic clamp (HEC) studies which revealed a
similar glucose disposal rate and peripheral sensitivity on both a HFD and normal chow
compared to WT, but a significant increase in HGP and decrease in % HGP suppression,
indicating insulin resistance at the hepatic level in PANTG mice [81]. These mice also presented
with significantly higher fasting glycemia compared to WT mice in addition to glucose
intolerance previous observed and an increase in overall weight gain [82, 96]. Mechanistically,
the PANTG mice displayed a decrease in phosphorylation of AMPK previously shown in an adPANDER acute model with consequential hepatic hyperlipidemia [51, 82, 96]. This first
genomically overexpressing PANDER murine model further supports PANDER’s proposed
enhancement of glucose intolerance and insulin insensitivity in-vivo.

PANDER Knockout Model
Lastly, in contrast to siRNA knockdown PANDER murine model, Cooperman et al.
generated a global PANDER knockout (PANKO) model, devoid of any circulating PANDER, to aid
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in elucidating PANDER’s biological roles [52, 60, 61, 62]. This mouse, generated by replacing
the first 2 exons of the PANDER gene including the transcriptional start site with a neomycin
cassette in the reverse order (Figure 4), was backcrossed onto a C57/129 genetic background
[60].

Figure 4: PANDER Gene Targeting Strategy. Illustration of the targeting strategy used when
creating the PANKO mouse, where a region of the PANDER promoter, UTR, transcriptional start site,
signal peptide, and first 2 exons were replaced with a Neomycin casette in the reverse order. The
Neomycin gene was flanked by a 4.3 kb and 2.9 kb arm of the PANDER gene, leading to its disruption
(adapted from Cooperman et al., 2010) [60].

In general, the PANKO mouse displayed glucose intolerance during a GTT due to an
impairment in insulin secretion and abnormal Ca2+ handling within pancreatic islets suggesting
that PANDER potentially affects calcium homeostasis in response to glucose [52, 60, 62].
Insulin levels were also elevated in the PANKO mice during a GTT, due primarily to a decrease
in insulin clearance within the liver [60]. The increase in insulin levels was accompanied by
similar levels of other hormones including leptin, c-peptide, glucagon, and amylin [60]. On the
other hand, the same PANKO mice, under hyperinsulinemic-euglycemic clamp conditions,
exhibited lower HGP and higher % HGP suppression, indicating a degree of hepatic insulin
sensitivity compared to wild-type (WT) mice [52, 60, 62]. This is accompanied by a significant
decrease in expression of G6Pase and PEPCK after an overnight fast and no effect on blood
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glucose levels [52, 54, 62]. When evaluated on a high-fat diet (HFD) for a 10 week duration,
the PANKO C57/129J mice presented with significantly lower blood glucose levels after both a
24 and 48 hour fast and glucose intolerance during GTT [52, 61, 62]. Interestingly, insulin
levels at all time points during a GTT were lower in PANKO mice compared to WT, where they
were previously elevated when fed normal chow [60, 61, 62]. Fasting expression of G6Pase and
PEPCK mRNA remained decreased even when PANKO mice were fed HFD, and overall weight
along with food consumption were similar [61]. As a whole, it appears that the loss of
circulating PANDER could act as a protectant against fasting hyperglycemia when being fed a
HFD for a minimum of 10 weeks by suppressing expression of gluconeogenic enzymes [52, 61,
62].

Role of PANDER in Glycemic Regulation

In-vitro and in-vivo data regarding PANDER suggest a potential role in glycemic
regulation, especially its response to nutrient stimulus. Interestingly, under physiological
conditions of insulin sensitivity and normal glucose tolerance, PANDER promotes these normal
processes by facilitating the secretion of insulin from β-cells, and insulin, as the dominate
molecule, will suppress HGP regardless of PANDER’s actions [52, 62]. As evidenced in the
PANDER murine models summarized above, it is only where there is an excess of PANDER in a
combination with one or more states of hyperglycemia, hyperinsulinemia, or hyperlipidemia,
that PANDER begins to exert negative effects on overall glycemic regulation [39, 52, 62]. By
using a type 2 diabetic murine model, the db/db mouse, where hepatic PANDER expression was
silenced by siRNA, hepatic lipogenesis, insulin resistance shown by a decrease in
phosphorylation through the insulin signaling cascade, and fasting hyperglycemia were all
abolished and enhanced glucose tolerance was restored [51, 62]. Additionally, Wilson et al.
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corroborated this evidence by measuring the serum PANDER levels in C57BL/6 mice considered
to be young and lean and observed a decrease in serum PANDER both fed and fasting
compared to aged, fat mice [54]. These aged, fat mice with natural elevated serum PANDER
levels also had higher fasting blood glucose levels compared to young, lean mice, further
indicating that under normal physiological conditions, PANDER will work to maintain normal
glycemia and HGP [52, 54]. The PANTG mouse model also exhibits fasting hyperglycemia and
decreased β-cell mass while on a HFD and increased hepatic triglyceride content compared to
WT proving that increased PANDER works with lipids to promote hyperglycemia whereas in
normal control mice, this is delayed, or even non-existant [52, 80, 82].

Role of PANDER in Type 2 Diabetes
Type 2 diabetes is generally defined by 3 hallmarks- hyperglycemia, hyperinsulinemia,
and hyperlipidemia which all exacerbate the progression of the disease. Perhaps the most
telling data regarding PANDER and its potential pathogenesis in type 2 diabetes is the effect
that it has on the liver to induce all 3 diabetes hallmarks [62]. Not only does PANDER bind to
the liver membrane shown through I125 labeling saturation studies, but its binding is highly
specific though there has been no elucidation of the PANDER receptor [62, 72]. Further,
treatment of hepatocellular liver carcinoma (HepG2) cells with PANDER inhibited insulinstimulated signaling beginning at IR, through Akt, suggesting that PANDER induces hepatic
insulin resistance [62, 72]. This is in addition to HEC studies on the PANTG corroborating
evidence that hepatic insulin resistance is induced by PANDER and HGP was upregulated in adPANDER and PANTG models [81]. Hyperglycemia is also driven by PANDER in that not only is
the PANDER promoter significantly stimulated by high glucose concentrations and HGP is higher

in-vivo, but PANDER enhances the expression of G6Pase and PEPCK as evidenced through ad-
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PANDER, PANKO models, and hepatocytes treated with PANDER exhibiting higher glucose
production [45, 49, 52, 54, 61]. The combination of increased HGP in clamp studies and
increased rate of gluconeogenesis with PANDER murine models having a higher fasting
glycemia makes PANDER responsible for at least 1 diabetic hallmark- hyperglycemia.
Hyperinsulinemia, both a cause and consequence of hyperglycemia, is evident in the
presence of PANDER as insulin stimulates the PANDER promoter and enhances PANDER
secretion from α-cells [52, 69]. Hyperinsulinemia, in turn, creates a compensatory increase in
glycemia through decreased insulin sensitivity and upregulating HGP, further increasing
PANDER expression and secretion from β cells [52]. Hepatic steatosis, serum triglycerides, and
expression of lipid metabolic genes are all upregulated in murine models overexpressing
PANDER in addition to recent evidence claiming that palmitic acid, a long chain fatty acid
molecule, significantly increases the expression of both PANDER mRNA and protein in murine β
TC6 cells [51, 52, 90]. This signifies that not only does PANDER enhance circulating and hepatic
hyperlipidemia, but it also promotes further hyperlipidemia. Taken together, all of the hallmarks
that define T2D also define an increase in PANDER expression, secretion, and action, ultimately
creating a vicious cycle of T2D initiation and progression aided by increased PANDER levels.
This makes PANDER an attractive therapeutic drug target in the treatment of T2D to slow or
even prevent the onset and progression of the metabolic abnormalities associated with T2D and
restore glucose tolerance and insulin sensitivity [52, 62].

Role of PANDER in Cancer
Most recently, within the last year, PANDER has evolved to be a topic of interest of the
realm of cancer research. PANDER was recently discovered in a number of human cancer cells
including human hepatocellular carcinoma cells, lung carcinoma cells, and even human colon
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cancer cells [75]. Interestingly, RNA interference (RNAi) experiments to silence PANDER
expression resulted in apoptotic cell death of both human colon cancer cells and lung carcinoma
cells, whereas the earliest PANDER experiments revealed that PANDER overexpression or
treatment induced apoptosis of β-cells through the CDKN1A/caspase-3 network [43, 44, 67, 75,
76]. The silencing of PANDER by RNAi that subsequently lead to apoptosis in cancer cells was
shown to be mediated by tumor protein 53 (p53), as it was significantly upregulated following
PANDER silencing [75]. Further, phosphorylation of p53 was increased when PANDER was
silenced, and when reversed, when p53 was silenced, PANDER-induced apoptosis was nearly
completely reversed [75].
Down-regulation of PANDER mRNA and protein levels was observed in oral squamous
cell carcinoma (OSCC) cells and primary patient samples compared to normal oral cells [73].
This downregulation of PANDER was attributed to microRNA (miRNA) upregulation in the 3’ UTR
of the PANDER gene, causing imperfect base pairing [73]. This was the first study that linked
PANDER expression (down-regulated, in this case) to the carcinogenesis of a specific cancer
type, oral squamous cell carcinoma, and characterized the cause of downregulation being that
of miRNA upregulation [73]. A similar downregulation of PANDER expression was also observed
in human gastric cancer where the lower PANDER mRNA levels in gastric cancer samples
correlated to greater depth of tumor invasion [74, 77]. Li et al. performed the first studies
evaluating the effects of the 7 different alternative splicing isoforms of PANDER in colon
cancers, specifically in 6 colon adenocarcinoma cell lines and tissues [74]. One PANDER isoform,
a 258 amino acid residue non-secretory form of PANDER (FAM3B-258), was found to be highly
upregulated in its expression in not only colon cancer cell lines but also colorectal
adenocarcinoma tissue samples, though tumor differentiation was poor [74]. Overexpression of
FAM3B-258 in colorectal carcinoma cells was shown to enhance cell invasion and migration
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through a Slug-dependent pathway, where the transcription factor Slug was highly expressed in
the cells overexpressing FAM3B-258 [74]. Slug will work with another transcription factor, Snail,
to downregulate to the expression of cell adhesion molecules and allow for invasion, both of
which were upregulated in FAM3B-258 overexpression cells [74, 77, 78]. Additionally, FAM3B258 enhanced colon cancer metastasis to the lung in nude mice, further confirming that FAM3B258 works with Slug to aide in cancer cell invasion and migration [74]. In summary, though
most research involving PANDER centers around its mechanism of action in glucose
homeostasis and the pathogenesis of type 2 diabetes, PANDER’s role in up/downregulating
various cancers is quickly emerging, as well, especially in oral, gastric, and colorectal cancers.

Other FAM3 Family Members
When PANDER was discovered in 2002 (known as FAM3B at the time), it was only one
gene in a family of 4 putative genes including FAM3A, FAM3C, and FAM3D [34]. Though FAM3B
is arguably the most researched of all 4 genes, research on FAM3A, FAM3C, and FAM3D,
though minimal, has begun to surface. First, FAM3D was initiall found to be highly expressed in
the placenta and to a smaller extent in the small intestine, known to be very hyperproliferative,
indicating that FAM3D could be important in cell proliferation [34]. In 2012, de Wit et al.
revealed that FAM3D, the human ortholog of murine Oit1, was robustly expressed in the
gastrointestinal tract of humans and was affected by nutrient stimulus [83]. Levels of FAM3D in
human plasma was shown to be decreased after fasting, and more interestingly, after being on
a HFD for 3 weeks, FAM3D levels were elevated postpradially after also being fed a HFD shake
compared to subjects being on a LFD [83]. FAM3D has also been linked to diabetes melllitus in
patients suffering with pancreatic adenocarcinoma, but has never been elucidated further [83,
84]. The expression pattern of FAM3D, though limited in extensive research, is similar to that of
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PANDER and is affected by nutritional status in a similar manner, specifically in its response to
HFD.
FAM3A, the first gene identified in the ORF algorithm, is composed of 230 amino acid
residues and is expressed in a wide array of tissues, including the most robust expression in the
heart, followed by the liver, pancreas, colon, and small intestine, among others [34, 39]. Zhou

et al. is the only group thus far to report on FAM3A’s activity in the liver, where they
determined that PPARγ overexpression enhanced FAM3A expression in HepG2 cells which was
reversed with PPARγ agonists in HepG2 cells and primary hepatocytes [35, 39]. The FAM3A
promoter was also highly activated by PPARγ and and PPARγ was shown to bind directly to its
putative binding site in the FAM3A promoter, the peroxisome proliferator response element
(PPRE) [35, 85]. Site-directed mutagenesis of PPRE deteriorated FAM3A’s promoter response to
PPARγ and in-vivo, the upregulation of the FAM3A promoter resulted in an increased
phosphorylation of Akt [35]. Like that of PANDER and FAM3D, FAM3A evidence suggests a
potential role in controlling hepatic lipogenesis through PPARγ and further control hepatic
metabolism [35, 39].
FAM3C, also known as interleukin-like epithelial-mesenchymal transition (EMT) inducer
(ILEI), as its name suggests, is integral in the process of EMT and breast cancer progression,
much different than that of its other family members [40, 86]. Initial reports on FAM3C
centered around its robust expression in the ear and the laminar retina, where it where it was
identified as perhaps inducing nonsyndromic hearing loss [36, 37, 40, 86, 87]. FAM3C’s name
was changed to ILEI after Waerner et al. discovered that it was a molecule involved in EMT,
where epithelial cells’ transition to cancer begins, as evidenced in its altered expression and
correlation to tumor metastasis [40, 86]. ILEI is expressed to its highest levels in the process of
EMT and overexpression of ILEI exclusively in mammary epithelial cells promotes EMT and
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tumor metastasis of the cells [86]. Further, transforming growth factor-β (TGF-β), a known EMT
inductor, will enhance the activation of ILEI by inhibiting the action of heterogeneous nuclear
ribonucleoprotein E1 (hnRNP E1) and TGF-β activated translation (BAT) element that work to
suppress ILEI translation [40, 88, 89]. Through this TGF-β activation of ILEI, and conformation
of ILEI’s role in EMT shown through siRNA silencing, EMT progresses and the expression of ILEI
(especially in the cytoplasm) correlates positively with breast cancer patient outcome [40, 88,
89]. FAM3C is the first member of the FAM3 family to have a suggested role in the progression
of cancer, while FAM3A and FAM3D relate to PANDER in their roles in maintaining metabolic
homeostasis. Nevertheless, the family with sequence similarity 3 has proven to be an integral
part of normal human processes and all members have implications in the pathogensis of
diseases including cancer and type 2 diabetes mellitus.

Project Summary and Specific Aims
Type 2 diabetes (T2D), a disease affecting 371 million people around the world as of
2012, is expected to reach that of epidemic proportions by affecting just over 440 million people
by the year 2030 [10, 11]. The effects that T2D has taken and has yet to take globally,
nationally, and economically greatly exacerbate the need to further understand proteins
involved in insulin signaling, their regulation, and how they contribute to the onset and
progression of the disease. Pancreatic-Derived Factor, or PANDER, is a novel protein hormone
discovered in 2002 that was shown to be highly expressed within pancreatic islets, co-secreted
with insulin, and stimulated by glucose [34, 66]. For these reasons, in addition to the fact that
PANDER binds to the liver membrane and inhibits the activation of critical insulin-signaling
molecules, it is believed that PANDER plays a role in glucose homeostasis [72]. Initial acute
murine studies show that C57BL/6 mice overexpressing PANDER hepatically exhibit impaired
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glucose tolerance, elevated gluconeogenic gene expression, and increased hepatic lipogenesis
[51, 54]. However, previous studies of PANDER knockout mice on a mixed genetic C57/129J
background also revealed glucose intolerance, similar insulin sensitivity to WT, impaired insulin
secretion from pancreatic β-cells, yet reduced mRNA expression of gluconeogenic enzymes [54,
60]. These results are further convoluted by a single report claiming knockdown of PANDER
resulted in an attenuation in hepatic steatosis, insulin resistance, and hyperglycemia [51].These
novel contradictory findings further emphasize the importance of understanding PANDER’s role
in glucose homeostasis and hepatic insulin signaling in a genetically pure animal knockout
model.
The following project being proposed will aim to determine the phenotype of the
PANKO-C57 PANDER knockout mouse in addition to elucidating the mechanism of selective
hepatic insulin resistance caused by PANDER shown in previous in-vivo and in-vitro data.
Previous in-vivo studies have not provided a clear mechanism of PANDER’s action in a purebred C57BL/6J murine model and therefore have reported conflicting results. Ultimately, by
characterizing a PANDER knockout mouse on C57BL/6J background, perhaps one of the best
understandings of how PANDER affects central cellular metabolic processes and its implications
in type 2 diabetes will be uncovered. Based on in-vitro data and initial characterization of the

PANKO mouse on C57/129J mixed genetic background, we hypothesize that the PANKO-C57
mice will exhibit improved glucose tolerance and insulin sensitivity with enhanced hepatic insulin
signaling. The specific aims to test this hypothesis are as follows:
Specific Aim 1: Determine the overall glycemic regulation and metabolic characterization in the
pure PANKO-C57BL/6 mouse
1.1: Determine fasting glycemia, hormonal, and plasma triglyceride differences
between PANKO-C57 mice and WT mice
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1.2: Characterize post-prandial differences between PANKO-C57 and WT mice

via

glucose and insulin tolerance testing
Specific Aim 2: Elucidate the mechanism of PANDER in hepatic signaling
2.1: Characterize the impact of PANDER on the PI3Kinase-Akt node of hepatic
signaling
2.2: Determine the expression of gluconeogenic enzymes G6Pase and PEPCK
2.3: Measure differences in hepatic glycogen content and hepatic triglyceride
content
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CHAPTER TWO: INITIAL PHENOTYPING OF PANDER KNOCKOUT C57BL/6 MOUSE

Rationale
As presented previously, PANDER animal models, both transgenic and knockouts to
date, have provided confounding evidence in terms of PANDER and its role in glycemic
regulation, as a number of the models are acute. Transgenic mice overexpressing PANDER
present with overall higher blood glucose levels and impaired hepatic insulin signaling at Akt
[51, 54]. siRNA mediated knockdown of PANDER has been shown to enhance insulin signaling
at the PI3K-Akt node in addition to decreasing hepatic lipogenesis [51]. However, a single
report regarding a generated PANDER knockout mouse suggested glucose intolerance with a
lower HGP and decreased expression of gluconeogenic enzymes, but this animal, though not
acute, was on a genetically mixed C57/129 background, not optimal for phenotypic
characterization [54, 60]. Compilation of discordant in-vivo data regarding PANDER begs a
knockout model on a purebred C57BL/6 background for complete characterization and novel
findings as to PANDER’s complete role in-vivo [52].
The C57/129 PANKO mouse, after its standard initial characterization, was subsequently
backcrossed for 8 generations onto the C57BL/6 background to allow for optimal phenotypic
characterization, as C57BL/6 mice are the most widely used inbred mouse strain in scientific
studies [91, 92]. This resulting congenic PANKO strain, after a total of 10 generations of
backcrossing, ended up being approximately 99.9% homozygous at the specific affected null
locus to any additional PANKO mice born, ensuring no interference from a mixed genetic
background in phenotyping [91]. Once backcrossed on to C57BL/6 background, the mice were
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backcrossed an additional generation at The Jackson Laboratory (Bar Harbor, ME) where they
were submitted under strain name B6.129S6-Fam3btm1Bkht/J for maintenance before being
shipped to Moffitt Cancer Center’s Stabile Vivarium (Tampa, FL). The mice were further
backcrossed one more additional generation upon arrival at Moffitt Cancer Center for murine
colony derivation, allowing for the optimal 10 generation backcross on to the C57BL/6
background for maximum homozygosity in the colony [91].
By utilizing this PANDER knockout model on a C57BL/6 background, we hypothesized
that the PANKO-C57 mouse would exhibit enhanced glucose tolerance complemented with an
increase in insulin sensitivity shown through metabolic tests with lower fasting glycemia and
hormonal levels to be evaluated using high-sensitivity assays [60].

Experimental Design & Methods

Murine Colony Acquisition, Care, and Maintenance
3 PANKO-C57 and 5 total C57BL/6 breeding pairs were obtained from Jackson
Laboratory (Bar Harbor, ME) after being backcrossed an additional generation and genotype
confirmed for animal husbandry and colony start-up. The mice were maintained in standard
breeding cages with standard pellet bedding at Moffitt Cancer Center’s Stabile Vivarium
(Tampa, FL) given normal chow (Purina®) ad-libitum with constant access to water in
accordance with approved breeding Institutional Animal Care and Use Committee (IACUC)
protocol 4005 M. Any pups born were weaned at 3-4 weeks of age before being ear-tagged for
identification and tail-snipped for DNA genotyping. Mice were then subsequently transferred to
the approved Research protocol (4071 R) for experimentation. All maintenance and procedures
conducted adhered to approved IACUC protocols at the University of South Florida and Moffitt
Cancer Center (Appendix B & C).
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Murine DNA Genotyping
DNA was extracted from all PANKO-C57 and WT pups at

3-4

weeks

of

age

for

conformation of respective genotype. 0.5 centimeter long tail snips were obtained from each
mouse using a single edge razor blade (Fisher Scientific, Pittsburgh, PA). Tails snips were
subsequently placed in Eppendorf tubes (Hauppauge, NY) with volumes indicated of Buffer ATL
and Proteinase K at 56°C overnight for tail dissolving according to manufacturer’s protocol in
DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA). DNA isolation was further completed
according to manufacturer’s protocol and concentrations/purities were determined using a
Nanodrop (Thermo Scientific, Wilmington, DE). Eluted DNA samples were used in PCR
amplification under standard cycling conditions where each sample was amplified using WT
primers (-338 Kpn and -35 TA) and KO primers (-338 Kpn and KONeoP2) to confirm no
heterozygous mice were present [45, 60]. DNA samples were subsequently run in a 1%
agarose gel with 2 μl ethidium bromide for DNA visualization. Gels were visualized using Fuji
LAS4000 imager (FujiFilm GE Healthcare, Pittsburgh, PA) and genotype was confirmed through
presence of specific banding patterns base on WT (approx. 850-1000 bp) or KO (approx. 400500 bp) primers used and compared to a standard 1 Kb Plus DNA Ladder (Invitrogen, Carlsbad,
CA).

Measurement of Fasting Glycemia
4-5 month old male and female PANKO-C57 and WT C57BL/6 mice were fasted
overnight (>16 hours, long-term) by removal of all food, leaving water, for blood glucose
reading after the overnight fast. The same procedure was followed when short-term fasting
glycemia was measured where male and female PANKO-C57 and WT mice were fasted for 4
hours by removal of food from cages. A TRUEtrack blood glucose meter (Walgreens) with
respective strips was utilized to evaluate the glucose content of approximately 1 μl of blood
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obtained via a tail vein puncture using a sterile lancet. All values and concentrations were
analyzed via GraphPad Prizm (Version 5) and statistical significance (p<0.05) between KO and
WT was determined using 2-tailed Student t-test.

Body Weight Measurements
Body weights of PANKO-C57 and WT mice were measured (Beckman Digital Scale) in
the mornings after feeding normal chow ad-libitum in 2-3 week increments. Weight
measurements began at 8 weeks of age after being weaned and continued to 21-23 weeks of
age. All weights were measured in grams and were analyzed by the mean and SEM for each
group at each time point weight was measured. All weights were analyzed via GraphPad Prizm
(Version 5) and statistical significance (p<0.05) between KO and WT was determined using 2tailed Student t-test.

Measurement of Hormonal Analytes
Evaluation of hormonal differences was conducted using a MAGPIX® Luminex (Austin,
TX) Multiplexing Instrument and plasma (Figure 5). Blood was obtained via a submandibular
vein poke from male PANKO-C57 mice at 2 months and 5 months of age along with WT male
mice of the same ages using 18-gauge PrecisionGlide needles (BD Diagnostics, Franklin Lakes,
NJ) and microvette tubes. Samples were kept on ice until processing. Samples were then
centrifuged for 10 minutes at 13.2 rpm for plasma separation, the plasma supernatant removed
and placed in an Eppendorf (Hauppauge, NY) tube, then stored at -80°C until use. The
MAGPIX® panel that was used included antibody-immobilized beads for the following analytes:
Amylin, Resistin, Glucagon, Insulin, C-Peptide, and Leptin. The assay was conducted using
approximately 10-30 μl of fasting plasma used in triplicate in accordance with the
manufacturer’s protocol for the Mouse Metabolic Magnetic Bead Panel (Millipore, Billerica, MA).
Results were then analyzed based on a Mouse Metabolic Hormone Standard provided with the
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assay kit, using WT C57BL/6 plasma as a control, and xPONENT® data analysis system
(Luminex). All values and concentrations were analyzed via GraphPad Prizm (Version 5) and
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student ttest.

Figure 5: Luminex Multiplexing Concept & Protocol. This figure represents the concepts and 2-day
protocol involved in the MAGPIX® Luminex system, beginning with conjugation of the serum sample
added to the plate to the immobilized magnetic beads. Steps 2 and 3 are completed before quantitative
measurement in Step 4 using xPONENT® analysis.

Measurement of Plasma Corticosterones
Corticosterone levels were measured longitudinally in serum from male PANKO-C57 and
WT mice at 2 and 5 months of age after an overnight fast. Serum was obtained from mice as
described above in Measurement of Hormonal Analytes. Corticosterone ELISA assay was
performed according to manufacturer’s protocol provided in the ENZO® Life Sciences
Corticosterone ELISA Kit (ADI-900-097) (Farmingdale, NY). Results were obtained via VersaMax
Microplate Reader (Molecular Devices, Sunnyvale, CA) with SoftMax® Pro software at a
wavelength of 405 nm for optimal absorbance according to assay protocol. All values and
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concentrations, presented in ng/mL, were analyzed via GraphPad Prizm (Version 5) and
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student ttest.

Measurement of Plasma Triglycerides
Plasma triglyceride content was evaluated by adhering to the manufacturer’s protocol
provided in Triglyceride Quantification Kit (Abcam- ab65336, Cambridge, MA) with plasma from
male PANKO-C57 and WT mice at 2 months and 4-5 months of age obtained as described
above. All samples were performed in triplicate. The assay was conducted at plasma dilutions of
1:10 and 1:50 using water as a control to ensure values were within the standard curve given
with the kit. The protocol pertaining to the colorimetric assay was utilized and samples were
analyzed using a VersaMax Microplate Reader (Molecular Devices) with SoftMax® Pro software
at a wavelength of 570 nm for optimal absorbance. All values and concentrations, presented in
nM, were analyzed via GraphPad Prizm (Version 5) and statistical significance (p<0.05) between
KO and WT was determined using 2-tailed Student t-test.

Glucose Tolerance & Insulin Tolerance Testing
For glucose-tolerance testing (GTTs), 4 month old male and female PANKO-C57 and WT
mice were fasted overnight (>16 hrs) and injected intraperitoneally with 2 grams of glucose
(Fisher Scientific) per kilogram of mouse body weight. Blood glucose levels were obtained as
described above at 0, 15, 30, 60, and 120 minutes post glucose injection [60]. For insulintolerance testing (ITTs), 4 month old male and female PANKO-C57 and WT mice were fasted
for 4 hours (approx. a week after GTT was completed) and injected intraperitoneally with 1.0
units of insulin (NovoLog®, Novo Nordisk, Plainsboro, NJ) per kilogram of mouse body weight.
Blood glucose levels were measured as described previously at 0, 15, 30, 60, 90, and 120
minutes post-injection of insulin [60]. All numerical values were analyzed via GraphPad Prizm
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using SEM and statistical significance (p<0.05) was determined at each time point between KO
and WT using 2-tailed Student t-test.

Confirmation of PANKO-C57 and WT Genotypes
Prior to experimentation, all pups born to PANKO-C57 or WT parents were genotyped
using DNA extracted from tail snips and amplified using primers for the KO and WT alleles as
described in Experimental Design & Methods. In all, 203 pups were born, and 219 mice
including the parent generation were genotyped. Mice born to PANKO-C57 and WT parents
were analyzed for the presence of both the WT allele using -338 Kpn Forward and -35 TA
Reverse primers, and the KO allele using the -338 Kpn Forward and KONeoP2 Reverse primers
as previously described [45, 60]. Amplification of the PANKO allele resulted in an approximately
500 bp product in PANKO-C57 mice, while amplification of the WT allele was confirmed in
C57BL/6 WT mice by the appearance of a band between 850 and 1000 bp using the respective
primer sets (Figure 6A). Further, the absence of either the PANKO or WT gene was confirmed in
WT and PANKO mice, respectively, through PCR amplification and subsequent gel
electrophoresis to ensure only homozygous mice were being used in experimentation. Negative
amplification of the PANKO gene in WT mice was confirmed by the absence of a DNA fragment
at approximately 500 bp in gel electrophoresis, when compared to positive (WT mouse with
PANKO primers) and negative (WT mouse with WT primers) controls (Figure 6B). The same
negative amplification was observed when attempting to amplify the WT allele in PANKO-C57
mice. The absence of DNA bands was observed in gel electrophoresis between 850 and 1000
bp, further indication that the PANKO-C57 mice were not heterozygous, but rather homozygous
for knockout of the PANDER gene (Figure 6C). It was also confirmed that none of the WT mice
that were genotyped and used in experimentation contained the KO allele, either.
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Figure 6: PCR-Amplified PANKO-C57 and WT Allele Confirmations. 1% agarose gel
electrophoresis for genotype verification of PANKO-C57 and WT mice, using 1 Kb Plus DNA Ladder
(Invitrogen) as standard in all figures, with 500 bp and 850 bp fragments labeled. (A) Lanes 1-8:
depicting PANKO DNA fragment at around 500 bp, Lanes 9 & 10: showing WT fragment between 850 and
1000 bp. (B) Lanes 1 & 2: positive and negative control of WT mice with KO primers and WT mice with
WT primers, respectively, and Lanes 3-11 confirming the absence of the KO gene as in the positive
control. (C) Lanes 1-6: negative amplification of the WT allele in 6 KO samples. Shown by the absence of
a fragment between 850 and 1000 bp in lanes 1-6.

PANKO-C57 Mice Exhibit Lower Fasting Glycemia Short and Long Term
Characterization of the PANKO-C57 began with analyzing fasting blood glucose levels
after a short (4 hours) and long term (overnight, approx. 16 hours) fast to determine overall
insulin sensitivity. As stated previously, siRNA knockdown PANDER mice presented with lower
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blood glucose levels as well as PANKO mice on C57/129 background, but only on HFD after 24
and 48 hour fasts, and neither of these were global knockouts on C57BL/6 backgrounds [51,
52, 61, 62]. PANKO-C57 male mice at 4 months of age exhibited a significantly lower fasting
glycemia compared to age and sex matched C57BL/6J WT mice after fasting for 4 hours where
the average PANKO-C57 blood glucose was 169.3 mg/dl + 6.9 versus WT average blood
glucose of 225.8 mg/dl + 30.5 (P < 0.05) (Figure 7A). This same trend, with an increased
significance, was also observed after a long-term fast of the same age and sex matched
PANKO-C57 and WT mice, where PANKO-C57 mice presented with an average blood glucose of
117.1 mg/dl + 5.9 versus WT average of 156.2 mg/dl + 12.2 (Figure 7B).
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Figure 7: Male PANKO-C57 Mice have Lower Fasting Glycemia Short and Long Term. (A):
Blood glucose measurements (mg/dl) obtained from a tail vein poke after a short term fast for 4 hours
and measured using standard glucometer, n= 8-11, P < 0.05. (B): Blood glucose measurements (mg/dl)
measured after an overnight (long-term) fast from tail vein poke as previously decribed, n= 12-15, P <
0.01.

The same procedure to measure fasting glycemia was performed with female PANKOC57 and WT mice that were 4 months of age. After a short-term fast, blood glucose
concentrations of PANKO-C57 and WT females were very similar, where the average PANKOC57 concentration was 169.7 mg/dl ± 30.38 versus WT blood glucose concentrations of 181.1
mg/dl ± 39.10 (n.s.) (Figure 8A). Greater differences were observed in female blood glucose
concentrations after a long-term overnight fast, though differences were not significant.
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PANKO-C57 females blood glucose average concentrations were 139.4 mg/dl ± 20.90 versus
189.8 mg/dl ± 30.88 female WT average blood glucose concentration (n.s.) (Figure 8B).
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Figure 8: Female PANKO-C57 Display Lower Average Fasting Glycemia Trend After Short and
Long Term Fast. (A) Blood glucose concentrations were measured (mg/dl) from PANKO-C57 and WT
female mice after 4 hour fast through a tail vein poke and measured using a glucometer (n= 6-10). (B)
Following a long-term overnight fast, female PANKO-C57 and WT mice blood glucose concentrations were
measured via tail vein (n= 7-12).

PANKO-C57 Mice Display Increased Body Weights Longitudinally
In order to characterize any effect that PANDER has in-vivo in terms of weight and
weight gain, body weights of both male and female PANKO-C57 and WT mice were measured
as described above in Experimental Design & Methods. PANTG pancreatic overexpressors
displayed an increase in overall weight gain, whereas PANKO C57/129 mice were shown to
have similar weights to WT when fed HFD. This lead us to determine if the knockout of PANDER
in C57BL/6 mice would induce a difference in murine body weights that was not previously
noted in any previous PANDER knockdown/knockout model [61, 82]. Beginning at 8 weeks of
age, male PANKO-C57 mice displayed a significant increase in body weight at an average of
25.16 g ± 0.35 compared to male WT mice averaging 23.32 g ± 0.3 (P < 0.001). This trend
continued every 2-3 weeks weight was measured up to 23 weeks of age where PANKO-C57
mice averaged 37.20 g ± 1.05 versus WT mice averaging 30.59 g ± 0.45 (P < 0.001) (Figure
9A).
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Longitudinal body weight measurements were also performed every 2-3 weeks for
female PANKO-C57 and WT mice to determine any significant differences as there were in the
male mice. It was found that at 8 weeks of age, female PANKO-C57 mice were also significantly
heavier than WT mice, where the average PANKO-C57 weight was 20.18 g ± 0.5 versus an
average weight of 18.20 g ± 0.26 for WT mice (P < 0.001). The trend, though diminishing in its
significance, also continued through to 21 weeks of age in the females where PANKO-C57
females weighed an average of 25.84 g ± 1.17 compared to WT average weight of 23.01 g ±
0.52 (P < 0.05) (Figure 9B).
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Figure 9: PANKO-C57 Mice Body Weight Measurements Trend Heavier than WT Mice. (A) Male
longitudinal weights of PANKO-C57 and WT mice (in grams) obtained every 2-3 weeks from 8-23 weeks
of age using a Beckman digital scale each time weights were obtained (n= 10-27). (B) Comparison of
female PANKO-C57 and WT mice obtained beginning at 8 weeks of age through to 21 weeks of age,
weighing every 2-3 weeks as described in Experimental Design & Methods (n= 9-22).

Differential Expression of Metabolic Hormonal Analytes in PANKO-C57
To elucidate the mechanism of the significant observed decreased fasting glycemia in
the male PANKO-C57 mice, a MAGPIX® Luminex (Austin, TX) Multiplexing approach was
employed to determine concentrations of the fasting concentrations of the hormones insulin,
glucagon, leptin, c-peptide, amylin, and resistin as described in Experimental Design & Methods.
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While the previous PANKO C57/129 mice displayed an increase serum insulin concentration only
measured during metabolic testing with no differences in leptin, c-peptide, glucagon or amylin
and an ad-PANDER overexpressor model showed no difference in glucagon levels, neither
contributed to an explanation for overall fasting glycemia, perhaps due to their genetic
backgrounds [52, 54, 60].
To begin, overnight fasting plasma obtained from male PANKO-C57 and WT mice at 2
months of age revealed significantly decreased insulin content in PANKO-C57 plasma compared
to WT at 105.4 pg/mL + 36.4 versus 487.8 pg/mL + 34.6 (P < 0.001), respectively, with the
same trend at 5 months of age, though not significant (Figure 10). Plasma glucagon levels were
similar in PANKO-C57 and WT mice at both 2 and 5 months of age, where levels in WT at 2
months and PANKO-C57 and WT at 5 months of age were below the minimal detectable content
for the assay and therefore could not be quantified (Figure 10). Leptin, an adipose tissuederived hormone known to be elevated in the plasma with increasing fat mass and obesity, was
significantly elevated in the plasma of PANKO-C57 mouse at both 2 and 5 months of age
(Figure 10) [93, 94]. At 2 months old, PANKO-C57 mice plasma leptin levels were 779.7 pg/mL
+ 76.6 versus WT plasma leptin levels of 253.3 pg/mL + 84.8 (P < 0.01), and though
significance was lost at 5 months of age, plasma leptin concentrations in PANKO-C57 mice
remained nearly 5 times higher than levels in WT mice. Lastly, c-peptide, the connecting
peptide between insulin’s A and B chain in the proinsulin molecule used as a diagnostic tool for
the measure of insulin in diabetes, was significantly decreased in PANKO-C57 at 2 months of
age compared to WT mice, 386.0 pg/mL + 104.9 vs. 830.8 pg/mL + 46.98, respectively (P <
0.01), coinciding with the decreased insulin levels at 2 months (Figure 10) [95]. Interestingly,
when plasma c-peptide levels were evaluated at 5 months of age, PANKO-C57 mice displayed a
significant increase in c-peptide concentration at 686.5 pg/mL ± 100.8 compared to WT c-
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peptide levels of 388.0 pg/mL ± 40.84 (P < 0.05) where they displayed a decrease in insulin
levels from 2 to 5 months. Amylin and resistin, the last 2 hormones analyzed, were not able to
be quantified due to the constraints of the assay in terms of quality controls and concentrations
of both analytes fell below the minimal detectable range on the standard curve.
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Figure 10: Longitudinal Serum Hormonal Analyte Concentrations in PANKO-C57 and WT
Mice. 2 and 5 month longitudinal Luminex multiplexing analysis of insulin, glucagon, leptin, and cpeptide in PANKO-C57 and WT plasma fasted overnight, concentrations shown in pg/mL (n= 4-6). Not
included: amylin and resistin, as concentrations were too low to quantify.

Similar Corticosterone and Plasma Triglyceride Concentrations in PANKO-C57
Corticosterones, the murine version of glucocorticoids, were previously shown to be the
primary cause of fasting hyperglycemia in ad-PANDER overexpressing mice compared to WT
mice [52, 54]. Further, Li et al. reported that in their ad-PANDER hepatic overexpressor, there
was an increase in serum triglycerides [51]. To further determine if plasma corticosterone levels
contributed to the lower fasting glycemia in the PANKO-C57 and if increased serum triglycerides
potentially contributed to the increased body weight with the plasma levels of leptin, assays
were conducted to measure each in PANKO-C57 and WT fasting plasma. Corticosterone levels
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were almost identical between PANKO-C57 and WT mice at both 2 and 5 months of age, where
fasting corticosterone averages were lower at 5 months than at 2 months of age (Figure 11A).
At 2 months, PANKO-C57 fasting corticosterone concentrations averaged 54.74 ng/mL ± 1.65
versus WT averages of 57.00 ng/mL ± 10.31 (n.s.). These averages decreased in each cohort
to 40.48 ng/mL ± 11.75 in PANKO-C57 mice versus 41.11 ng/mL ± 17.96 in WT mice at 5
months of age (n.s.).
When examining plasma triglyceride content, at 2 months of age, PANKO-C57 mice
presented with significantly higher plasma triglycerides at an average of 164.9 nM ± 7.939
compared to WT mice at 140.7 nM ± 7.716 (P < 0.05) (Figure 11B). There was a switch in
trend of longitudinal plasma triglyceride content at 5 months of age in the same PANKO-C57
and WT mice, where PANKO-C57 mice displayed a lower plasma triglyceride concentration than
WT mice, 147.2 nM ± 11.93 versus 158.7 nM ± 10.97 (n.s.), respectively. Interestingly, not
only did PANKO-C57 plasma triglyceride content decrease longitudinally, but WT plasma
triglyceride content increased longitudinally from 2 to 5 months of age (Figure 11B).
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Figure 11: Plasma Corticosterone and Triglyceride Levels in PANKO-C57 and WT Mice. (A)
Overnight fasting plasma obtained from both PANKO-C57 and WT mice longitudinally at 2 and 5 months
of age were analyzed for corticosterone content using Corticosterone ELISA Kit (ADI-900-097)
(Farmingdale, NY), shown in ng/mL (n= 4). (B) Plasma triglyceride content from overnight fasting
PANKO-C57 and WT mice was analyzed using Triglyceride Quantification Kit (Abcam- ab65336,
Cambridge, MA), presented in nM (n= 5).
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PANKO-C57 Mice Display Enhanced Glucose Tolerance in Metabolic Tests
GTTs previously performed on male PANKO mice on C57/129 background revealed
significant glucose intolerance as evidenced by increased blood glucose levels during GTT [60].
This glucose intolerance was accompanied by increased insulin levels at every time point during
the GTT, both the result of impaired Ca2+ handling in pancreatic islets and impaired insulin
clearance, respectively [60]. To explore whether these same traits were also apparent in
PANKO-C57 mice, both male and female PANKO-C57 and WT mice underwent GTTs at 4
months of age. Male PANKO-C57 mice displayed lower blood glucose levels at every time point
during the GTT, 3 of which were significantly lower- 15 minutes, where PANKO-C57 blood
glucose levels were 415.9 mg/dL + 45.9 versus WT blood glucose levels of 561.1 mg/dL + 33.2
(P < 0.05), 60 minutes, where PANKO-C57 mice had blood glucose levels of 397.7 mg/dL +
46.3 versus WT blood glucose levels 592.8 mg/dL + 8.3 (P < 0.01), and at the final time point
in the GTT at 120 minutes where PANKO-C57 mice presented with blood glucose readings of
290.1 mg/dL + 48.2 versus WT blood glucose levels of 472.3 mg/dL + 37.1 (P < 0.05) (Figure
12A). This trend was confirmed by area under the curve (AUC) determination, where the
PANKO-C57 AUC was significantly lower than WT (P < 0.01), a further indication that male
PANKO-C57 mice are more glucose tolerant than male WT mice (Figure 12B).
This trend of enhanced glucose tolerance was also observed to a milder extent in
PANKO-C57 females where, at the first 4 time points during the GTT, female PANKO-C57 blood
glucose levels were decreased, and significantly decreased at 30 minutes post i.p. glucose
injection where female PANKO-C57 blood glucose concentration averaged 378.4 mg/dl + 72.79
versus WT at 531.3 mg/dl + 33.88 (P < 0.05) (Figure 12C). This mild enhancement in glucose
tolerance was also corroborated by a decrease in PANKO-C57 GTT AUC, though it was not
significant (Figure 12D).
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Figure 12: GTT of PANKO-C57 Male and Female Mice Reveals Enhanced Glucose Tolerance.
(A) glucose tolerance test (GTT) of male PANKO-C57 and WT mice showing average blood glucose
(mg/dl) at each time point (in minutes) post 2 g/kg intraperitoneal glucose injection (n= 8-13). (B) Area
under the curve (AUC) of male GTT shown in A. (C) GTT of female PANKO-C57 and WT mice depicting
blood glucose readings (mg/dl) using glucometer at 0, 15, 30, 60, and 120 minutes post intraperitoneal
glucose injection at 2g/kg concentration (n= 7-12). (D) AUC of female GTT shown in C.

PANKO-C57 Mice Reveal Similar Insulin Sensitivity in Insulin Tolerance Test (ITT)
In addition to GTTs done at 4 months of age to characterize overall glucose tolerance,
the same PANKO-C57 and WT mice underwent ITTs to characterize their peripheral sensitivity
in response to a bolus injection of insulin on the C57BL/6 background. The previous PANKO
C57/129 mouse were shown to have no difference in peripheral insulin sensitivity shown by ITT
when fed both HFD for 5 and 10 weeks and normal chow, though generally, blood glucose
levels were slightly higher in the PANKO C57/129 at each time point [60, 61]. The same was
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also true for Ad-PANDER overexpressing mice and the PANTG mouse, where blood glucose
levels (shown as % of baseline) were similar to WT during a GTT [52, 81, 82]. Additionally,
another hepatic Ad-PANDER overexpressing model showed via a minimal model analysis, where
mice are anesthetized during experimentation, that PANDER ultimately contributed to an overall
decrease in insulin sensitivity [51].
Like the PANKO C57/129 mice, PANKO-C57 males showed no significant difference in
raw blood glucose concentrations from 0-60 minutes during the ITT, though their blood glucose
levels were trending lower than WT. Interesting, at 90 and 120 minutes of the ITT, the trend
switched and the PANKO-C57 blood glucose average was higher than that of the WT mice,
though differences in blood glucose measurements were not significantly different (Figure 13A).
The similarity in blood glucose levels during the ITT was confirmed by AUC analysis, where the
AUC for PANKO-C57 and WT were virtually the same 24490 ± 2048 versus 25610 ± 3558,
respectively (n.s.), though PANKO-C57 AUC was slightly lower (Figure 13B). When evaluating
the % from baseline change in blood glucose concentrations during the ITT, where timepoint 0
is considered 100%, or baseline, the similarity between PANKO-C57 and WT insulin sensitivity
became more profound, as did the trend reversal at 90 minutes, where PANKO-C57 mice
average blood glucose % from baseline, 121.8 % ± 13.76, was significantly higher than WT at
73.38 % ± 15.01 (P < 0.05) (Figure 13C). % from baseline change in blood glucose in PANKOC57 mice remained elevated at 120 minutes compared to WT, as well, though the difference
was not considered significant. The AUC of % from baseline change in blood glucose of PANKOC57 and WT mice was also not significantly different, though PANKO-C57 AUC was slightly
elevated compared to WT (13320 ± 1205 versus 12080 ± 2192, respectively), potentially due
to the trend reversal at 90 and 120 minutes (Figure 13D).
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Figure 13: Male PANKO-C57 and WT Similarities of Blood Glucose in ITT. (A) Male PANKO-C57
and WT raw blood glucose numbers (mg/dl) during ITT at 0, 30, 60, 90, and 120 minutes post
intraperitoneal insulin (1U/kg) injection recorded using glucometer (n= 8-12). (B) AUC of male ITT raw
blood glucose readings in Figure A. (C) Male PANKO-C57 and WT blood glucoses as % from baseline
during ITT, where 0 minute reading was baseline, calculated from values at each timepoint in Figure A (P
< 0.05) (n= 8-12). (D) AUC of % from baseline blood glucose values during ITT for males shown in
Figure C.

Though female mice previously showed no gross differences in metabolic analysis
regarding PANDER in-vivo, differences in insulin sensitivity via ITTs have not been reported in
C57BL/6 PANDER knockout mice [60]. Overall, when evaluating insulin sensitivity in female
PANKO-C57 mice during an ITT and observing the raw blood glucose readings at each time
point, there was no difference compared to female WT mice (Figure 14A). This was confirmed
by differences in AUC of the ITT that were not significant, though PANKO-C57 average AUC was
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slightly higher than WT (Figure 14B). Further, the same was true for female blood glucose
concentrations during an ITT calculated as % change from baseline, where measurements at all
time points were highly similar and correlated with the raw data (Figure 14C). The AUC for
female blood glucose during an ITT as % change from baseline was also similar, despite the
increase in WT AUC compared to PANKO-C57 (Figure 14D).
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Figure 14: ITT Measurement of Insulin Sensitivity in Female PANKO-C57 and WT Mice. (A)
Raw blood glucose numbers (mg/dl) from female PANKO-C57 and WT after 4 hours of fasting during ITT
at 0, 30, 60, 90, and 120 minutes post intraperitoneal insulin (1U/kg) injection recorded using glucometer
(n= 7-11). (B) AUC of female ITT raw blood glucose readings in Figure A. (C) Female PANKO-C57 and
WT blood glucoses as % from baseline during ITT, where 0 minute reading was baseline, calculated from
values at each timepoint in Figure A (n= 7-11). (D) AUC of % from baseline blood glucose values during
ITT for males shown in Figure C.
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Summary of Initial PANKO-C57 Phenotypic & Metabolic Characterization
At the conclusion of the initial phenotyping experiments on the PANKO-C57 mice,
several novel findings were observed when taking into consideration previous in-vivo PANDER
studies. First, PANKO-C57 male mice have a significantly lower overall fasting glycemia
compared to WT mice after fasting for both 4 hours and overnight. This is in contrast to the
female PANKO-C57 fasting glycemias, which, though had a decreased trend, were not
significantly lower. When the decrease in fasting glycemia was discovered at 4-5 months of age
in the males, it was also accompanied by a decrease in overnight fasting insulin with a
surprising increase in c-peptide, increased leptin, and no difference in glucagon or
corticosterone levels compared to WT mice. When measured in plasma from the same PANKOC57 mice at 2 months of age in comparison to age and sex-matched WT mice, insulin was also
decreased with the concordant decrease in c-peptide, leptin trended to be increased as well as
glucagon, and corticosterone levels were also no different. Plasma triglyceride content was also
significantly increased at 2 months old in the PANKO-C57 compared to 5 months old, where
plasma triglycerides trended decreased.
The male specificity of PANDER’s role in-vivo, as first evidenced by the measurement of
fasting glycemias, was also corroborated with enhanced glucose tolerance shown by GTTs and
significantly increased weight of male PANKO-C57s compared to WT. Though PANKO-C57
females also displayed significantly increased weights from 8-21 weeks of age, the trend of
enhanced glucose tolerance shown by GTT was not as pronounced. Peripheral insulin
sensitivity, however, was unaffected by the knockout of PANDER in both males and females as
ITTs showed similar blood glucose levels and % change from baseline in response to a bolus
injection of insulin.
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This initial phenotype, being male-dominant, suggests that the knockout of PANDER not
only decreases fasting glycemia and increases glucose tolerance through hormonal analytes
such as insulin, but it also facilitates a significant increase in weight, possibly through significant
increases in plasma leptin and triglyceride concentrations.
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CHAPTER THREE: HEPATIC INSULIN SIGNALING IN PANDER KNOCKOUT C57BL/6
MOUSE

Rationale

In-vitro, PANDER has been shown to bind to the liver membrane in HepG2 cells and
inhibit insulin signaling at the liver by preventing the phosphorylation of both the Insulin
Receptor (IR) and Insulin Receptor Substrate-1 (IRS-1) under insulin-stimulated conditions [39,
62, 72]. Further down the insulin signaling cascade, PANDER was also shown to inhibit the
insulin-stimulated activation of PI3K and phosphorylation of Akt, both critical insulin signaling
molecules, in a dose- and time-dependent manner [39, 62, 72]. These results were exacerbated
in in-vivo animal models of PANDER where different ad-PANDER overexpressors presented with
an increase in lipogenic (SREBP-1, FAS, PPARγ) and gluconeogenic enzyme expression (G6Pase
and PEPCK), and a decrease in phosphorylated Akt, AMPK, and FOXO1 protein expression [51,
54]. The first PANTG overexpressing mouse also displayed a decrease in phosphorylated hepatic
AMPK and ACC as well [82]. The initial phenotypes of various PANDER overexpressors has been
shown to both support and contradict the phenotype of the initial PANDER knockout models.
Concordant with the characterized overexpressing or transgenic models, PANDER knockout
mice on mixed genetic background or siRNA models present with a lower HGP with higher %
HGP suppression, lower expression of gluconeogenic enzymes and enhanced hepatic insulin
signaling (in siRNA knockdown models), but with glucose intolerance and hyperinsulinemia [51,
52, 54, 60]. The observed glucose intolerance in the previous PANDER knockout was attributed
to impaired insulin secretion and hepatic insulin clearance. However, these studies lack a
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concrete mechanism of action of hepatic signaling in a genetically pure model, like our PANKOC57 model. In addition, the mixed genetic background PANDER knockout mouse was never
thoroughly investigated in the context of altered hepatic signaling despite the presence of
increased HGP suppression.
Using the genetically pure PANDER knockout mouse on a C57BL/6 background (PANKOC57), the effect PANDER is having on the mechanism of hepatic insulin signaling, hepatic
gluconeogenic enzyme expression, and glycogen content under fed and fasting conditions was
ultimately determined. We hypothesized that the PANKO-C57 mice would have enhanced
hepatic insulin signaling as demonstrated by increased phosphorylation of critical signaling
molecules such as p-PI3K, Akt, and AMPK, along with increased downstream effector pathways
such as in regard to increased glycogen synthesis and lipogenesis.

Experimental Design & Methods

SDS-PAGE Western Blotting of Fasting and Fed Liver Protein
The liver tissue was obtained from male PANKO-C57 and WT mice at 5 months of age in
the fasting (>16 hrs, overnight) or fed (insulin-stimulated) state. For fasting samples, mice
were fasted overnight by removing all food and livers were extracted the next day after humane
euthanization in accordance with experimental IACUC compliance (Appendix C). Livers were
placed in CryoTube Vials (Thermo Scientific) and were subsequently flash frozen in liquid
nitrogen and stored at -80°C until use. For insulin-stimulated livers, mice were fasted for 4
hours and injected with 2 units/kilogram of insulin (NovoLog) before humane euthanization and
flash freezing of whole livers. Serum was also collected 15-minutes post-injection of insulin in
insulin-stimulated mice and just prior to euthanization in fasted mice. The SDS-PAGE gels were
prepared using 100 mg of liver tissue homogenized using a TissueRuptor (Qiagen) in a
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TPER/HALT Protease and Phosphatase inhibitor cocktail (Thermo Scientific). The supernatant of
the liver lysate was quantified using a Pierce BCA Protein Assay (Thermo Scientific) following
manufacturer’s protocol and analyzed using a VersaMax Microplate Reader (Molecular Devices).
20-50 μg of the liver lysate was then loaded into a 10% tris/glycine Mini-PROTEAN® TGX™
Precast Gel (BioRad) SDS-PAGE with Precision Plus Protein™ WesternC™ Ladder (BioRad) to
determine protein size. Transferring of the gel to a PVDF membrane was then performed using
iBlot® semi-dry transfer technology per the manufacturer’s protocol provided (Invitrogen). The
membrane was then blocked overnight at 4° (or for 2 hours at room temperature), rocking
constantly, using StartingBlock Blocking Buffer (Thermo Scientific) and was probed for the
presence of IRS-1, p-IRS-1, p-PI3K, SREBP-1 (all 4 from SantaCruz Biotechnologies), Akt, p-Akt,
AMPKα, p-AMPKα, Acetyl CoA (ACC), p-Acetyl CoA (p-ACC), CREB, p-CREB, p-FOXO1, Glycogen
Synthase, p-Glycogen Synthase, and GAPDH as a loading control (all 12 from Cell Signaling
Technology) (Appendix A) at a 1:1,000 dilution in 10 mLs of StartingBlock Blocking Buffer
overnight at 4°C. Blots were then washed and respective secondary antibodies, whether antirabbit (BioRad), anti-mouse (BioRad) or rabbit-anti-goat (Santa Cruz) were added at a 1:3,0001:5,000 dilution in 10 mLs of StartingBlock Blocking Buffer with 1 μl of Precision Protein
StrepTactin-HRP conjugate (BioRad) for illumination of the protein ladder for 1 hr at RT. Blots
were then washed and developed using Pierce ECL Western Blotting Substrate (Thermo
Scientific) and imaged using a Fuji LAS4000 imager (FujiFilm GE Healthcare). Once imaged, the
blots were then stripped using Restore Western Blot Stripping Buffer (Thermo Scientific),
shaking, at 37°C, blocked for > 2 hours at room temperature, rocking, and re-probed using
another antibody. ImageJ was used in densitometric analysis of western blot images and all
values and concentrations were analyzed via GraphPad Prizm (Version 5) and statistical
significance (p<0.05) between KO and WT was determined using 2-tailed Student t-test.
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Measurement of Hepatic Triglyceride Content
To measure hepatic triglyceride content in PANKO-C57 and WT livers, fasting and
insulin-stimulated liver samples were obtained from PANKO-C57 and WT mice as described
above for SDS-PAGE western blotting. 100 mg of liver tissue was homogenized in 1 mL of 5%
Triton X-100 and heated at 99°C for 5 minutes before being cooled to room temperature, then
heated again for solubilization of all triglycerides and centrifuged for 2 minutes at top speed.
Samples were then diluted 10-fold and used in the Triglyceride Quantification Kit (Abcamab65336) following manufacturer’s protocol in triplicate for each sample and at dilutions of 1:10
and 1:100. The colorimetric assay was utilized and samples were analyzed using a VersaMax
Microplate Reader (Molecular Devices) with SoftMax® Pro software at a wavelength of 570 nm
for optimal absorbance, as it was for serum triglyceride measurement described previously. All
values and concentrations, presented in nM, were analyzed via GraphPad Prizm (Version 5) and
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student ttest.

Evaluation of Hepatic Glycogen Content
To measure the differences in hepatic glycogen content between PANKO-C57 and WT
mice, 10 mg of previously collected liver tissue from overnight fasted and insulin-stimulated
mice was used. The 10 mg of liver tissue was homogenized in 200 μl of deionized water. The
liver homogenate was then boiled, centrifuged, and the supernatant was collected and frozen at
-80°C until use in accordance with the manufacturer protocol provided in the Glycogen Assay
Kit (Abcam- ab65620). The assay was completed according to manufacturer’s protocol for the
colorimetric assay and samples were read at 570 nm using VersaMax Microplate Reader
(Molecular Devices). The assay was performed in triplicate for every sample using water as a
control, and each sample was analyzed not only quantitatively but qualitatively observing color
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change for samples that appeared off the standard curve. Each sample was also analyzed in
dilutions of 1:10 and 1:100 as to ensure that one of the two data sets coincide with the
standard curve (0.0004 mg/mL – 2 mg/mL). All values and concentrations (presented in μg/μl
or in fold change) were analyzed via GraphPad Prizm and statistical significance (p<0.05)
between KO and WT was determined using 2-tailed Student t-test.

Measurement of PEPCK and G6Pase Expression via RT-PCR
To examine the expression of gluconeogenic enzymes within the livers of the PANKOC57 and WT mice, livers were harvested and flash frozen from fasting and insulin-stimulated
mice as described in SDS-PAGE Western Blotting methods. In order to prepare the lysate for
RNA extraction, approximately 20 mg of liver tissue was homogenized in a mixture of Buffer
RLT (Qiagen) & BME in a 1:100 dilution BME:RLT Buffer using a TissueRuptor (Qiagen). The
supernatant, as a result of centrifuging, was then transferred to a gDNA eliminator column
provided in the RNeasy Plus Mini Kit (Qiagen) to rid the sample of any remaining genomic DNA
contaminants. Then, after a series of washes using ethanol and buffers provided with the kit
according to the manufacturer’s protocol, the RNA was eluted using RNase-free water (Thermo
Scientific). The RNA was then quantified along with determination of their purity using a
NanoDrop (Thermo Scientific), and then subsequently frozen in the -80°C freezer until use. For
real-time RT-PCR analysis, primer/probes for G6Pase, PEPCK, and 18s rRNA internal control
(Applied Biosystems, Life Technologies, Grand Islands, NY) were used with the TaqMan Reverse
Transcriptase systems (Applied Biosystems) and StepOne Plus ™ Systems (Life Technologies)
for mRNA detection. All samples were run in triplicate with deionized water serving as a
negative control to ensure there is no false amplification. Expression results were normalized to
the 18s rRNA expression and relative levels were determined using the 2-ΔΔCt method [9]. All
values were analyzed via GraphPad Prizm (Version 5) and statistical significance (p<0.05)
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between KO and WT was determined using 2-tailed Student t-test, presented as fold change
from WT.

Measurement of Plasma High-Density Lipoprotein (HDL) and Low-Density
Lipoprotein (LDL) Cholesterol
Plasma was obtained from 2 month old fasting PANKO-C57 and WT mice as previously
described in Measurement of Hormonal Analytes and used in HDL and LDL/VLDL Cholesterol
Assay Kit (Abcam- kit ab65390) according to manufacturer’s protocol. HDL and LDL were
separated in the beginning of the assay and analyzed separately to ensure accurate
concentration determination of each. Each sample was run in triplicate with a water control and
concentration was analyzed using a VersaMax Microplate Reader (Molecular Devices) at 570
nm. All values and concentrations (presented in μg/μl) were analyzed via GraphPad Prizm and
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student ttest.

Fasting PANKO-C57 Mice Exhibit Enhanced Hepatic Insulin Signaling
Previous data regarding PANDER murine models and insulin signaling have thus far been
convoluted and inconclusive due to overall differences in models where signaling was
characterized. 2 different ad-PANDER overexpressing models suggested that PANDER disrupts
the activation of FOXO1, AMPK, and Akt, in addition to enhancing signaling through CREB to
induce fasting hyperglycemia [51, 54, 62]. Additionally, these accounts were further
corroborated by the PANTG where levels of phosphorylated AMPK and ACC were decreased due
to PANDER overexpression [96]. However, the complete elucidation of PANDER’s effects on the
entire insulin signaling cascade has never been fully evaluated in any in-vivo model until this
PANKO-C57 characterization.
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Figure 15: Overnight Fasting Hepatic Signaling in PANKO-C57 and WT Mice. Figure depiction of
10% SDS-PAGE gels loaded with 20-50 μg of liver lysate protein from overnight fasted PANKO-C57 and
WT mice outlined in Experimental Design & Methods above. All primary antibody dilutions presented were
1:1000 with goat-anti-rabbit (BioRad) secondary antibody dilutions of 1:3000-1:5000. Images presented
are representative of multiple replicate western blots that were analyzed (n= 3).

After fasting overnight, PANKO-C57 mice display an overall decrease in protein
expression levels of IRS-1 (Figure 15). However, beginning at phosphorylated-PI3K and
continuing down through p-Akt, p-ACC, p-AMPK, p-GS and mature SREBP-1c, all protein
expressions are increased, indicating an enhancement of phosphorylation activity in the insulin
signaling cascade (Figure 15). All of these increases in protein phosphorylation between
PANKO-C57 and WT mice are relative to total levels of each respective target protein and
normalized to GAPDH levels serving as loading control for each individual mouse. Additionally,
levels of SREBP-1c precursor, the transcription factor attached to the endoplasmic reticulum
(ER) and nuclear envelope released in times of sterol-depletion to generate the mature SREBP1, were similar between PANKO-C57 and WT mice (Figure 15) [103]. Glycogen Synthase (GS)
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levels appeared similar between both groups, but when comparing phosphorylated-GS levels,
PANKO-C57 mice displayed an overall increase in protein expression, indicating that in the
fasting state in these mice, the GS protein is inactivated and glycogenolysis is occurring. The
increase in phosphorylation of these insulin signaling proteins, including GS, indicates an
enhancement in overall insulin signaling in PANKO-C57 mice in the fasting state. Unfortunately,
due to technical limitations with regard to lack of successful detection of target protein by
western analysis, phosphorylated IRS-1, total CREB, phosphorylated CREB, and phosphorylated
FOXO1 protein levels were unable to be properly measured despite utilizing commercially
available antibodies that were generated for detection of target proteins and previous reports
were unable to be corroborated in PANKO-C57 and WT C57BL/6 mice.

Insulin-Stimulation Enhances Hepatic Insulin Signaling in PANKO-C57
Expression of insulin signaling proteins in response to insulin stimulation in the PANTG
murine model revealed an overall decrease in expression levels of both phosphorylated AMPK
and ACC, as it did in the fasted state, compared to total levels of the same proteins [96]. Apart
from in-vivo models, HepG2 cells infected with ad-PANDER for only 48 hours displayed a
significant decrease in levels of phosphorylated Akt and FOXO1 after various lengths of times of
insulin treatment, further demonstrating PANDER’s negative regulatory effects on insulin
signaling on the liver in-vitro [51]. However, any further characterization of affected protein
levels of insulin signaling proteins post-insulin stimulation has remained to be characterized
compared to fasting levels in the same murine models, especially in the PANKO-C57 pure
PANDER knockout model.
15 minutes after insulin stimulation in PANKO-C57 mice, expression of IRS-1 appears to
be slightly decreased compared to WT mice (Figure 16).
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Figure 16: Insulin-Stimulated Effect on Hepatic Signaling Protein Expression in PANKO-C57.
Protein expression measured as outlined in Experimental Design & Methods using 20-50 μg of liver
protein lysate from PANKO-C57 and WT mice injected with insulin. PVDF membranes with transferred
proteins were incubated with primary antibodies at 1:1000 dilution and goat-anti-rabbit secondary
antibody (BioRad) at 1:3000-1:5000 dilution in StartBlock (Thermo Scientific).

However, insulin-stimulated levels of p-PI3K were highly upregulated in the PANKO-C57 with an
unexpected minimal decrease in p-Akt levels compared to WT mice, though protein expression
levels are different in each mouse compared to total Akt levels (Figure 16). Both mature SREBP1c and SREBP-1c precursor expression levels were increased in the PANKO-C57 when
stimulated with insulin in striking difference to fasting levels, where there was no difference in
SREBP-1c precursor expression between the PANKO-C57 and WT mice. Further, insulinstimulated p-AMPK and p-ACC expression levels appeared to be similar in both PANKO-C57 and
WT mice (Figure 16). Lastly, expression of phosphorylated GS was lesser in PANKO-C57 mice
compared to WT mice where there appeared to be no significant differences, if any, in nonphosphorylated GS levels in both cohorts of mice. All protein expression intensities were
compared to their respective total protein levels for each mouse when examining
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phosphorylated protein expression and all proteins were normalized to GAPDH protein loading
control (Figure 16).

Decreased Fasting Hepatic Triglyceride Content in PANKO-C57 Mice
The PANTG overexpressing mouse was recently shown to display an increase in hepatic
triglyceride concentration while fed a normal chow diet compared to WT mice, much like that of
an Ad-PANDER overexpressing model that revealed significantly higher liver triglyceride content
[51, 82]. Surprisingly, an additional Ad-PANDER murine model revealed decreased liver
triglycerides while fasting, opposite of what was observed in the hepatic Ad-PANDER
overxpressor [51, 54]. Further, the siRNA PANDER knockdown model revealed a reversal of
hepatic steatosis in db/db mice, but hepatic triglyceride concentration has never been evaluated
in a C57BL/6 PANDER knockout, or the previously characterized PANKO C57/129 model until
now [51, 54].
Evaluation of hepatic triglyceride content in male PANKO-C57 mice revealed an
approximate 4-fold increase in triglyceride concentration when stimulated with insulin, where
concentrations were 6.149 nM ± 1.595 versus WT concentrations of 1.517 nM ± 0.7263,
though values were not significant (Figure 17). After fasting overnight, interestingly, the
PANKO-C57 male mice displayed a significant decrease in hepatic triglyceride content compared
to WT mice, 7.021 nM ± 1.131 versus 10.87 nM ± 0.2170, respectively (P < 0.05) (Figure 17).
Also interesting to note, hepatic triglyceride content of WT mice was significantly increased (P <
0.01) in the fasting state compared to insulin-stimulated hepatic triglyceride concentrations. WT
triglyceride concentration was approximately 6-fold higher in fasting compared to insulinstimulated conditions, whereas PANKO-C57 hepatic triglyceride content was similar in fasting
and fed conditions.
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Figure 17: PANKO-C57 Mice Hepatic Triglyceride Concentrations Fasted and InsulinStimulated. Comparisons of PANKO-C57 and WT hepatic triglycerides using 100 mg of either overnight
fasting or insulin-stimulated liver sample and measured via Triglyceride Quantification Kit (Abcamab65336). Concentrations presented in nM, P < 0.05 denoted by single asterisk (n = 3 for each group).

PANKO-C57 Mice Exhibit Increased Fed Hepatic Glycogen Stores
To date, the only differences observed in glycogen stores in PANDER murine models has
been in the PANTG model, where glycogen stores were significantly increased while being fed
HFD [82]. No differences in glycogen stores were observed in the previous PANKO C57/129
mouse, prompting the measurement of glycogen concentrations in the PANKO-C57 in both the
fasting and insulin-stimulated conditions, as glycogen storage and glycogenolysis are central
hepatic metabolic processes [54].
Insulin-stimulated hepatic glycogen concentrations were significantly increased in the
PANKO-C57 mice where their glycogen concentrations were 142.7 μg/μl ± 17.16 versus WT
glycogen concentration at 1.169 μg/μl ± 0.1085 (P < 0.01) which correlated to a 122.1 fold
increase in glycogen stores over WT (P < 0.01) (Figure 18 A & B). After having been fasted
overnight, glycogen stores were depleted in both PANKO-C57 and WT mice, where PANKO-C57
mice had a lower concentration of hepatic glycogen at 1.737 μg/μl ± 0.4636 versus WT mice
with fasting hepatic glycogen concentration at 3.226 μg/μl ± 0.4003 (n.s.) which resulted in an
almost 2 fold increase in glycogen stores within WT mice (Figure 18 A & C).
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Figure 18: Hepatic Glycogen Stores in PANKO-C57 and WT Mice. (A) Comparison of hepatic
glycogen concentration between PANKO-C57 and WT mice, presented in μg/μl, in the insulin-stimulated
(2U/kg of insulin) and overnight fasting conditions (n= 3). (B) Fold change between WT and PANKO-C57
hepatic glycogen stores, presented in fold change above WT, in the insulin-stimulated state shown on the
left in A. (C) Fold change in hepatic glycogen concentrations, given in fold change above/below WT, in
the fasting state shown on the right in A.

Gluconeogenic Enzyme Expression is Upregulated in Fed PANKO-C57 Mice
Gluconeogenesis is the main contributor to HGP after approximately 8-12 hours of
fasting, and PANDER has been linked to upregulating expression of gluconeogenic enzymes,
G6Pase and PEPCK, in ad-PANDER overexpressing mice after only 3-4 hours of fasting after a
GTT, contributing to an overall increased fasting glycemia [2, 25, 54]. siRNA PANDER
knockdown db/db mice and the C57/129 PANKO mouse displayed a decrease in both G6Pase
and PEPCK, and this decrease was observed in the PANKO C57/129 mouse after an overnight
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fast, surprisingly, with no reports of gluconeogenic enzyme expression while insulin-stimulated
[51, 54].
Surprisingly, when evaluated under insulin-stimulated conditions, PANKO-C57 mice
displayed not only a significant increase in G6Pase expression compared to WT (45.36 ± 10.71
vs. 3.807 ± 1.160, P < 0.01), but an almost 8-fold higher relative gene expression of PEPCK
(86.28 ± 49.8 vs. 11.08 ± 4.452, respectively), though not significant (Figure 19A).
Interestingly, as opposed to the significant decrease in expression of G6Pase and PEPCK in the
C57/129 PANKO mice observed after an overnight fast, the PANKO-C57 mice displayed no
significant difference in expression of either G6Pase or PEPCK, though PEPCK expression was
trending lower than that of WT (Figure 19B) [52]. Fasting relative expression levels of G6Pase
in PANKO-C57 mice were similar to that of WT mice where relative gene expression was 3.117
± 1.215 versus WT G6Pase expression levels of 2.956 ± 1.062 (n.s.). Further, fasting
expression levels of PEPCK in PANKO-C57 averaged 3.756 ± 1.339 versus WT mice at 5.105 ±
1.378 (n.s.).
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Figure 19: Fasting and Insulin-Stimulated Relative Gene Expression of G6Pase and PEPCK in
PANKO-C57 Mice. (A) Using the 2-ΔΔCt method for determination of relative expression levels, insulinstimulated expression of G6Pase and PEPCK was measured in RNA isolated from 10 mg of liver tissue
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from PANKO-C57 and WT mice (n= 4-6). (B) Overnight fasting relative expression of G6Pase and PEPCK
measured in isolated hepatic RNA and calculated using 2-ΔΔCt relative gene expression calculation (n= 6).

Higher HDL and Lower LDL Plasma Cholesterol in PANKO-C57 Mice
Overexpression of hepatic PANDER was previously shown to have little effect on
HDL/LDL cholesterol concentrations specifically within the liver, though the same hepatic
PANDER overexpressing mice interestingly displayed a significant increase in serum VLDL
concentrations [51]. Hepatic PANDER siRNA knockdown in db/db mice also revealed
significantly lower circulating VLDL in contrast to hepatic overexpressors [51]. The PANTG
mouse, on the other hand, was reported to display an increase in plasma HDL cholesterol with
similar LDL plasma cholesterol levels, perhaps suggesting a role for PANDER in maintaining
circulating cholesterol biosynthesis, which we evaluated in fasting PANKO-C57 plasma obtained
from mice at 2 months of age [82]. Like the PANTG, the PANKO-C57 presented with an increase
in plasma HDL cholesterol with a concentration of 0.701 μg/μl versus WT plasma HDL
concentration of 0.480 μg/μl (Figure 20). Plasma LDL cholesterol, on the other hand, and unlike
that of the previous PANDER siRNA knockdown model, trended slightly lower in the PANKO-C57
at a concentration of 0.075 μg/μl versus WT plasma LDL cholesterol concentration of 0.103
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Figure 20: Plasma HDL/LDL Cholesterol Concentrations in PANKO-C57 and WT Mice. 2 months
HDL (left) and LDL (right) cholesterol measurement from fasting plasma of PANKO-C57 and WT mice
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shown in concentration of μg/μl using HDL and LDL/VLDL Cholesterol Assay Kit (Abcam- kit ab65390)
(n= 1).

Summary of Hepatic Signaling Mechanisms in PANKO-C57 Mice
The complete elucidation of hepatic insulin signaling in PANKO-C57 mice provides not
only clarity to earlier contradictory evidence, but also novel findings regarding PANDER’s role in
effecting hepatic insulin signaling, particularly during the fasted state. The PANKO-C57 mice
displayed an upregulation of all of the critical insulin signaling molecules in the insulin signaling
pathway after an overnight fast, where 3 of the 5 protein expression differences were
significant when analyzed using densitometry, denoted by asterisks and shaded dark green in a
heat map (Table 1). This supports the idea that PANDER’s most severe effects are in the fasted
state as opposed to in insulin-stimulated conditions. When stimulated with insulin, the PANKOC57 mice displayed selectively different trends in protein expression within the insulin signaling
cascade as in the fasted state, though no values were significant or expression levels were not
different compared to WT (Table 1).
Table 1: Summary of Western Results Comparing Hepatic Signaling in PANKO-C57 versus WT
as a Heat Map Representation

Signaling
Molecule

IRS-1
p-PI3K
p-Akt
p-AMPK
p-ACC
mSREBP-1
p-GS

Fasting



*
*

*
**

Insulin
Stimulated




NC
NC



* Western results are shown in a heat map with up arrows (shaded in green) or down arrows (shaded in
red) denoting increased or decreased phosphorylation (normalized to total target protein and loading) or
abundance (for IRS-1), respectively. * denotes statistical significance according to densitometry and are
highlighted by a darker shade of red or green. NC refers to no change measured and is shaded in yellow.
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Beyond insulin signaling, the PANKO-C57 mice presented with increased hepatic
triglyceride content post-insulin stimulation but lower hepatic triglyceride content after an
overnight fast compared to WT mice. Glycogen stores were also significantly increased along
with hepatic triglycerides after insulin stimulation and were almost depleted after fasting
overnight. Interestingly, as opposed to previous PANKO C57/129 and siRNA PANDER
knockdown models, expression of gluconeogenic enzymes G6Pase and PEPCK were increased in
the PANKO-C57 after insulin stimulation and were similar to WT after fasting, though PEPCK
was evidenced to be slight decreased. Lastly, plasma levels of HDL cholesterol were higher with
decreased levels of plasma LDL cholesterol in the PANKO-C57 mice at 2 months of age
compared to age and sex matched C57BL/6 WT mice.
These novel findings discovered as a result of the elucidation of hepatic signaling both
fasting and insulin stimulated (fed) along with glycogen, triglyceride, and cholesterol
measurement in the PANKO-C57 indicate PANDER plays a significant role in affecting glycemic
regulation, particularly in the fasting state. Furthermore, PANDER also potentially affects hepatic
stores of glycogen and differentially affects gluconeogenic enzyme expression and HGP under
conditions of insulin abundance.
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CHAPTER FOUR: CONCLUSIONS

PANKO-C57 Compared to Previous PANDER Knockout/Knockdown Models
After complete phenotypic and hepatic signaling characterization of the global PANDER
knockout mouse on a C57BL/6 genetic background, the PANKO-C57 mouse, several similarities
and differences were discovered between the PANKO-C57, the previous PANKO C57/129 mixed
genetic PANDER knockout, and the acute ad-PANDER db/db siRNA PANDER knockdown mouse
(Table 2). The PANKO-C57, devoid of any circulating PANDER, exhibited an enhanced glucose
tolerance and decreased fasting glycemia, like that of the siRNA PANDER knockdown, but unlike
that of the PANKO C57/129 [51, 54, 60]. Interestingly, in full contrast to the siRNA knockdown
model, the PANKO-C57 presented with an overall increase in both plasma and hepatic
triglycerides, neither of which were even evaluated in the PANKO C57/129, suggesting that
PANDER may work through alternate mechanisms up or downregulate triglyceride synthesis
under different conditions [51, 60]. The fact that none of the 3 PANDER knockout/down models
display an enhanced peripheral insulin sensitivity indicates that PANDER’s effects are solely
focused on the liver to upregulate glucose output, as evidenced by the decrease in
gluconeogenic enzyme expression in both the PANKO C57/129 and the siRNA knockdown, but
not in the PANKO-C57, indicating an additional mechanism for their decreased fasting glycemia
[51, 54]. However, in light of the lack of decreased glconeogenic enzyme expression, the
PANKO-C57 has, thus far, been the only model to exhibit a decrease in fasting glycemia,
increase in hepatic glycogen stores, and enhanced hepatic signaling through critical insulin
signaling molecules involving p-PI3K, p-Akt, and SREBP-1, among others, which was not fully
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characterized in the siRNA knockdown model and not attempted in the PANKO C57/129 [51].
This suggests that the PANKO-C57, as opposed to comparable models, represents a more
enhanced phenotype for identification of PANDER function.
Table 2: Comparisons of PANDER Knockout C57/129 & db/db siRNA Knockdown Murine
Models to PANKO-C57

PANKO-C57 as an Improved PANDER Murine Model

Advantages
The

PANKO-C57

mouse

offered

great

advantages

in

terms

of

phenotypic

characterization and offered clarity, in addition to further understanding, of PANDER’s role in-

vivo. First, this PANKO-C57 mouse was the first and only PANDER model to depict significant
phenotypic differences between female PANKO-C57s and WT mice, including increases in body
weights and enhanced glucose tolerances, in addition to trending decreased fasting glycemia.
Though PANDER’s effects were ultimately determined to be male-dominant, as they are
regarding other PANDER murine models, shown by significant decreases in fasting glycemia and
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significant enhances in glucose tolerance in male PANKO-C57 mice, the differences observed
here in female PANKO-C57s is novel [54, 60, 82, 96]. Additionally, given that these PANKOC57s are on a purebred C57BL/6 genetic background, any abnormalities due to the genetic
background with heterozygosity and gene expression, which was the case with the PANKO
C57/129 co-isogenic strain, are abolished, ensuring in excess of 99% homology within the
breeding colony of the congenic PANKO-C57 strain [91, 92]. When compared to the mixed
genetic PANKO C57/129, the pure bred PANKO-C57 was able to exhibit traits such as enhanced
glucose tolerance, decreased fasting insulinemia, and differences in body weight and fasting
glycemic levels not previously observed in the PANKO C57/129 [54, 60, 61]. These observed
differences can only be attributed to the different genetic backgrounds, PANKO C57/129 versus
PANKO-C57, and suggest that the PANKO-C57 is the optimal PANDER knockout model. Also,
because the PANKO C57/129 mixed genetic mouse revealed defects in insulin secretion due to
improper calcium handling, it is possible that those defects are also present in the PANKO-C57
[60]. However, any of the possible effects of defective insulin secretion in the PANKO-C57 were
completely masked by the significantly enhanced hepatic insulin sensitivity that was not
observed in the PANKO C57/129.
Additionally, because the PANKO-C57 has integrated the null PANDER mutation into its
genome for transmission to all generations, there are multiple advantages to the PANKO-C57
over the acute siRNA PANDER knockdown db/db model. First, not only was siRNA knockdown
performed in a mouse accepted as a suitable model for type 2 diabetes, but siRNA knockdown
via tail vein injection was only performed 3 days prior to all experimentation [51, 53]. Because
knockdown of a gene via siRNA is considered transient in the case of this PANDER model, not
only is continuous application of the siRNA needed to elicit a long-term effect, but the efficiency
of delivery and off-target effects of the siRNA need to be taken into consideration as well [51,
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98]. The PANKO-C57 offers an advantage to this model in that the effects of the null PANDER
mutation are able to be studied longitudinally in these mice throughout their lifespan, from
weaning to euthanization. This allows us to observe not only the effects of globally knocking out
PANDER in these purebred C57BL/6 mice, but also to observe how the aging process effects
PANDER and perhaps the development of type 2 diabetes, considered an adult-onset disorder
[12-15]. Several assays and screenings presented in this study were able to be performed at 2
and 5 months in the same mice, whereas siRNA knockdown models were not due to the shortterm longevity of the siRNA effects [51, 98]. Further, the db/db mouse is known as a model of
type 2 diabetes because of a point mutation in the leptin receptor that results in abnormal
signal transduction along with gross obesity, leptin resistance, and type 2 diabetic hallmarks
[53]. It is potentially for this reason that such a difference in fasting plasma leptin
concentrations were observed in the PANKO-C57 that could not possibly be observed in the
siRNA knockdown model being that the siRNA was performed on a db/db mouse.

Limitations
Though the PANKO-C57 is considered to be on an optimal background to observe the
effects of and phenotype null mutations, there are limitations to this study [91, 92]. First, the
lack of a tissue-specific PANKO-C57 is a potential drawback to completely characterizing
PANDER’s implications in-vivo. To delineate the relative contribution of various tissue-derived
PANDER from the liver, intestine, and pancreas, an argument could be made that tissue-specific
knockouts pertaining to these PANDER producing tissues would further refine the synergistic
role of this molecule. Thus far, the PANTG has been the only tissue-specific PANDER
overexpressing murine model created apart from other transient/acute ad-PANDER models [81,
82, 96]. The PANTG, a pancreas-specific PANDER overexpressor, has shed light on many
inconsistencies presented in other PANDER overexpressing models, and the creation of either a
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pancreas or liver-specific PANDER knockout would allow for improved clarity regarding
PANDER’s effects on/in specific organs and tissues [81, 82, 96]. Additionally, the PANDER
receptor has yet to be elucidated. Though the crystal structure of PANDER was discovered early
this year, the lack of a definitive PANDER receptor greatly hinders not only characterizing
PANDER’s interactions, but also potential novel therapeutics in preventing PANDER’s actions
[40]. That’s not to say that the PANKO-C57 was lacking, in any way, valuable evidence that its
phenotypic characterization adds to our knowledge regarding PANDER.
Further limitations regarding this study involve the n, or the number of mice, involved in
each analysis. Though an n value of 3 is able to generate statistical significance, perhaps using
more mice in each of the studies would reduce the standard error from the mean (SEM) values
and allow for greater significance to be reached. Many of the PANKO-C57 studies presented
including body weight measurements, GTTs, ITTs, and fasting glycemic measurements here
involved up to 10-15 mice and sometimes greater, where the greatest differences to WT were
observed, but technical limitations involving multiple assay optimizations hindered the ability to
assess more mice. Further, PANKO C57/129 mice displayed decreased fasting glycemia with
decreased insulinemia when stimulated with glucose and decreased fasting G6Pase and PEPCK
when fed HFD for up to 10 weeks [61]. This insinuates that these PANKO C57/129 mice could
be offered some protection to developing fasting hyperglycemia, a hallmark of type 2 diabetes
and an effect of PANDER, by ingestion of a HFD [52, 61]. As a result of these findings in the
mixed genetic PANKO C57/129, it is plausible to say that the effects of HFD feeding should be
evaluated on PANKO-C57 mice also. The genomic deletion of PANDER in C57BL/6 mice could
potentially

offer

an

even

higher

degree

of

protection

against

hyperglycemia

and

hyperinsulinemia brought on by a HFD that was observed in the PANKO C57/129, given that the
PANKO-C57s already display a decreased fasting glycemia and insulinemia. Unfortunately, due
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to the time constraints regarding this project, the effects of HFD on PANKO-C57 glycemic
regulation and glucose homeostasis was not able to be determined (although initiated), but
should be considered in future directions regarding PANKO-C57 characterization.
Lastly, though hepatic insulin signaling was determined to be enhanced in the PANKOC57 in this study, inconsistencies remained regarding increased and similar gluconeogenic
enzyme expression in insulin-stimulated and fasting conditions, respectively. Previously, the
PANKO C57/129 and siRNA PANDER knockdown presented with decreased gluconeogenic
enzyme expression which was corroborated in the PANKO-C57 only in the fasted state based on
a non-statistical trend [51, 54]. To circumvent these inconsistencies and better understand HGP
within the PANKO-C57, a hyperinsulinemic-euglycemic clamp study should be performed and
this model may eventually be sent for clamp studies for this purpose. HEC studies are
considered to be the gold standard and optimal method for determining hepatic insulin
sensitivity, peripheral glucose utilization, insulin action, and HGP [97]. HECs were performed on
both the PANTG and the PANKO C57/129 mice and revealed increased and decreased HGP,
respectively, along with decreased and increased % HGP suppression, respectively, which
greatly added to the overall phenotypes observed in each mouse [60, 81]. These HEC studies
should optimally be utilized as a confirmatory measure for enhanced hepatic insulin sensitivity
observed in the PANKO-C57 via multiple western blots, however, due to technical and monetary
limitations, HEC studies were not able to be completed within the realm of this study.
Nevertheless, the findings regarding PANDER and the characterization of the PANKO-C57
murine model that were gained from this study, in light of the few limitations, are novel and
further corroborate evidence that PANDER plays a major role in glycemic regulation, particularly
at the hepatic level.
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PANDER’s Role in Glycemic Regulation & Type 2 Diabetes Based on PANKO-C57
PANDER’s association with type 2 diabetes has been characterized thus far in terms of

in-vitro data and findings primarily from acute ad-PANDER overexpressors and knockdown
models. However, with the characterization of the PANKO-C57 presented in this study, clarity
has been gained regarding PANDER’s actions in the fed, fasting, and type 2 diabetic states.

PANDER in the Fed State
In the fed state, based on previous PANDER data combined with novel findings from this
PANKO-C57 phenotypic characterization, upon ingestion of a meal, blood glucose will rise by the
release of broken down sugars and carbohydrates into the bloodstream, or glucose appearance
[1, 4, 5]. The rising blood glucose stimulates pancreatic islets to secrete both PANDER and
insulin from β-cells [66]. Given that exogenously produced PANDER does not affect insulin
levels or secretion in-vivo and PANKO C57/129 mice islets reveal improper calcium handling
resulting in decreased glucose stimulated insulin secretion, PANDER seems to further enhance
insulin secretion from pancreatic islets [52, 54, 60]. Insulin, being the dominate molecule, and
being further facilitated by PANDER, will bind to its respective IR on the hepatic membrane and
enhances insulin signaling, lipogenesis, and enhance hepatic glycogen stores [51, 72].
Additionally, insulin enhances PANDER secretion from α-cells, further allowing PANDER to
augment the effects of insulin and insulin sensitivity [52, 69]. All of these factors contribute to
the maintenance of euglycemia after meal ingestion when all other contributions to blood
glucose and glycemia are normal (Figure 21).
Interestingly, in the PANKO-C57, though there is no circulating PANDER to facilitate
insulin secretion and action, the mice display enhanced hepatic insulin sensitivity in the insulinstimulated (fed) state and respond greater to insulin than C57BL/6 WT mice. This is shown
through an upregulation of critical insulin signaling molecules including p-PI3K, p-Akt, and
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SREBP-1, stimulating increased hepatic triglyceride content, and significantly higher glycogen
stores. This could potentially be due to the fact that though PANDER assists insulin and
promotes its secretion from β-cells, insulin plays a counterregulatory role to PANDER. When
PANDER is no longer present, insulin’s effects are potent and unrivaled in-vivo, lending to the
fact that fasting PANKO-C57 mice are particularly more insulin sensitive than WT mice.
Additionally, when PANDER is knocked out on a pure C57BL/6 background and all other genetic
inconsistencies are eliminated, insulin is able to work maximally to enhance glucose
disappearance, observed in the PANKO-C57 mice where they exhibit enhanced glucose
tolerance through lower blood glucose levels during a GTT.

Figure 21: PANDER’s Predicted Actions in the Fed State Based on PANKO-C57 Model.
Depiction of PANDER’s role in the fed states where (1) ingestion of a meal increases blood glucose levels,
stimulating (2) pancreatic islets to secrete PANDER and insulin, where PANDER further allows for insulin
secretion and action from the islets and insulin’s affects dominate that of PANDER’s at the hepatic level
and allow for (3) enhanced insulin signaling, increased lipogenesis, and enhanced glycogen storage,
leading to (4) the further maintenance of euglycemia and insulin sensitivity (adapted from Wilson et al.
2011) [52].
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PANDER in the Fasting State
When fasting, PANDER’s mechanism of action is slightly less understood, but it has
appeared as though PANDER exerts a greater negative role on glycemia under fasting
conditions. Decreasing blood glucose levels stimulate the release of glucagon from α-cells in
pancreatic islets [1]. With regard to PANDER secretion from pancreatic α-cells, L-arginine, a
stimulator of glucagon, highly upregulates PANDER secretion in a dose-dependent manner [52,
69, 70, 71]. Surprisingly, insulin was also found to upregulate PANDER secretion from
pancreatic α-cells as well [69]. With the increase in glucagon and subsequent decrease in
circulating insulin, PANDER is allowed to dominate glycemic regulation over glucagon via either
a FOXO1 or CREB dependent pathway [51, 52, 54]. PANDER levels have been evidenced to be
increased in fasting db/db mice, and this increase in PANDER negatively impacts the liver
through FOXO1 and/or CREB to decrease basal insulin signaling and enhance HGP [51]. This
increase in HGP seen in the PANTG via HEC clamp studies and evidenced through increased
expression in gluconeogenic enzyme expression in ad-PANDER overexpressors, contributes to
an overall increase in fasting hyperglycemia and plasma insulin content [54, 82] (Figure 22).
The PANKO-C57 corroborates the siRNA PANDER knockdown model where decreased
fasting blood glucose levels were observed, though glucagon levels were similar in the PANKOC57 [51]. Although differences in FOXO1 and CREB (and p-CREB) levels were not able to be
observed in the PANKO-C57 due to technical limitations, hepatic insulin signaling was
upregulated, and levels of PEPCK were shown to be trending lower in PANKO-C57, indicating
that when fasting; PANDER does, in fact, dominate basal levels of insulin to increase HGP.
Because fasting plasma insulin levels were lower in the PANKO-C57 compared to WT, PANDER
could potentially be working through an alternate mechanism to enhance HGP and increase
fasting glycemia. Being that there was no significant difference in fasting plasma leptin levels in
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the PANTG overexpressor and the PANKO-C57 exhibited significantly increased plasma leptin
levels, this offers a suitable route for PANDER. Increases in leptin and leptin signaling in the
brain are associated not only with increased fat mass, but with enhances in hepatic signaling
through PI3K, suppression of HGP, and increased hepatic insulin sensitivity [96, 99, 100]. This
presents an attractive mechanism for PANDER to act through, where PANDER could potentially
act on/be secreted from the brain and decrease leptin signaling, ultimately leading to an
increase in HGP and decrease in hepatic insulin sensitivity. Further, the siRNA PANDER
knockdown db/db model with a known defect in leptin receptor signal transduction failed to
report an enhancement of expression in all insulin proteins, perhaps due to the fact that they
are lacking the synergism that exists between leptin and hepatic insulin sensitivity [51, 53]. As a
whole, evidence from the PANKO-C57 phenotype indicates that the complete knockout of
PANDER allows for enhanced basal insulin sensitivity when fasting, contributing to an overall
decrease in fasting glycemia.

Figure 22: PANDER’s Predicted Role in Glycemic Regulation in the Fasted State Based on
PANKO-C57. (1) When fasting, blood glucose levels decrease, which (2) stimulate α-cells in pancreatic
islets to secrete glucagon. Meanwhile, PANDER works either through a CREB or FOXO1 dependent
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pathway to (3) decrease hepatic basal insulin signaling and increase HGP leading to (4) an increase in
plasma insulin and increased glycemia.

PANDER in Type 2 Diabetes
Type 2 diabetes is a disease primarily characterized by 3 hallmarks- hyperglycemia,
hyperinsulinemia, and hyperlipidemia, all of which are caused by secretagogues that have been
shown to stimulate PANDER transcription and secretion [65, 66, 68, 69, 90]. When any/all of
these disease states and secretagogues are present, the pancreatic islets are stimulated to
further secrete PANDER and maintain basal levels of insulin. Because of the hyper conditions
and given that PANDER levels are increased in mice modeling type 2 diabetes, PANDER could
potentially stimulate its own secretion from both the pancreatic islets and hepatocytes, where
PANDER is also present [51, 62]. This allows PANDER to impart its counterregulatory actions on
insulin and bind to its putative target receptor on the liver to decrease insulin signaling, increase
HGP, and decrease glycogen stores. The culmination of these events further perpetuates
hyperinsulinemia, hyperglycemia, and hyperlipidemia as insulin and glucose are not being
utilized, but instead remain in circulation. Thus, it appears that PANDER promotes a vicious
cycle with regard to type 2 diabetes and facilitates the progression and potentially onset of the
disease hallmarks (Figure 23).
PANKO-C57 mice, to begin, present with not only decreased fasting glucose levels, but
also decreased fasting plasma insulin levels. This further supports the notion that PANDER is a
main causative agent of fasting hyperglycemia and the subsequent hyperinsulinemia (due in
part to counteraction of insulin resistance or potentially facilitation of insulin secretion), as was
observed in young PANTG mice [96]. In terms of hyperlipidemia, PANKO-C57 mice, though they
appear to be hyperlipidemic, they retain their hepatic insulin sensitivity, and the improved
hepatic insulin signaling through SREBP-1 accounts for this observed hyperlipidemia both
hepatically and in the plasma. In the fed, insulin-sensitive state, PANDER’s effects on glucose
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homeostasis are minimal, as insulin imparts inhibitory effects on PANDER action perhaps simply
by a concentration dependence. But when insulin resistance sets in, it appears as though insulin
is potentially no longer capable of sufficiently counterracting PANDER. Instead, it appears that
PANDER operates in a positive-feedback loop to enhance its own production from the
pancreatic islets. PANDER binding to the liver membrane may also further stimulate PANDER
expression and secretion from the liver in a similar positive feedback loop. PANKO-C57 mice are
a model of insulin sensitivity and glucose tolerance compared to the PANTG and other PANDER
overexpressors being that the PANKO-C57 mice, with no PANDER expression or secretion from
any tissues, display reversal of a majority of metabolic abnormalities present in these
overexpressors. With excess PANDER in circulation due to these disease hallmarks, all evidence
points to PANDER as a causative factor in the progression of type 2 diabetes by continually
increasing the severity of hyperinsulinemia, hyperlipidemia, and hyperglycemia and an attractive
target for therapeutics in the treatment of type 2 diabetes.

Figure 23: PANDER’s Predicted Role in Insulin Resistance and Type 2 Diabetes. In insulin
resistant and type 2 diabetic individuals, where (1) hyperinsulinemia, hyperglycemia, and hyperlipidemia
are present, (2) pancreatic islets secrete PANDER and insulin where PANDER is the dominant over insulin
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and leads to an increase in PANDER secretion from pancreatic islets and the liver. (3) PANDER will
decrease insulin sensitivity by decreasing hepatic insulin signaling, increasing HGP, and decreasing
glycogen stores contributing to (4) a vicious cycle of hyperinsulinemia, hyperglycemia, and hyperlipidemia
(adapted from Wilson, et al. 2011) [52].

Perhaps the most telling data regarding PANDER and its negative regulatory effects on
hepatic insulin sensitivity and fasting glycemia is its severe depleting effects on hepatic
glycogen stores. Being that the PANKO-C57 had an over 100-fold greater amount of glycogen in
the liver compared to WT and the PANTG revealed significantly decreased glycogen stores, this
could potentially represent an additional mechanism of PANDER to induce fasting hyperglycemia
[96]. We have concluded that the PANKO-C57 resembles that of an animal model of Glycogen
Storage Disease (GSD). GSD, specifically Type 1 GSD, is a disorder caused by deficiency of
G6Pase, an enzyme which performs the last step of gluconeogenesis and glycogenolysis to
hydrolyze a phosphate group from glucose, leaving free glucose to be exported into the
bloodstream [1, 2, 101, 102]. The disease, both in humans and in murine G6Pase-/- models,
ends up manifesting itself through the following symptoms: hypoglycemia, significant liver
enlargement, and hyperlipidemia both hepatically and in the serum, all of which were evident in
the PANKO-C57 [101, 102]. The striking similarities between GSD Type 1 models and the
PANKO-C57 could offer a potential mechanism for PANDER in increasing both fasting glycemia
and gluconeogenic enzyme expression apart from increases in corticosterones and CREB
signaling previously described [52, 54]. Additionally, GSD Type 1a is defined by a deficiency in
the catalytic activity of G6Pase, which could be represented in the PANKO-C57 in that though
the mice are not deficient in G6Pase expression (or PEPCK) in fasting or fed conditions shown
via RT-PCR, perhaps G6Pase is building up due to a defect in its activity but not in its
production [101, 102]. This then leads to a decrease in HGP, subsequent hypoglycemia, buildup of glycogen in the liver with an increased liver mass, and increased triglycerides in the
PANKO-C57. Lastly, with the recent findings involving PANDER and its role in various cancers
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including oral squamous cell carcinoma and gastric cancer, this PANKO-C57 mouse model may
offer future resources in the field of oncology [73, 77]. Given that PANDER expression was
recently discovered to be downregulated in both of the aforementioned cancer types, our
PANKO-C57 offers an optimal model to potentially study the progression of each cancer type in-

vivo [73, 77].

Final Thoughts and Summary
In conclusion, this novel phenotypic characterization of the first PANDER knockout
mouse on a C57BL/6J background offers valuable information regarding PANDER’s role in
glucose homeostasis and insulin sensitivity. Not only do these PANKO-C57 mice display a
significant increase in glucose tolerance and hepatic insulin sensitivity, but they exhibit an
enhanced expression of key insulin signaling molecules throughout the entire insulin signaling
cascade, indicating that PANDER disrupts insulin signaling as part of its detrimental actions on
insulin sensitivity. Further, PANKO-C57 mice exhibit lower fasting glycemic measurements with
decreased insulinemia and increased weights, perhaps to compensatory mechanisms involving
leptin signaling and glycogen storage. Taken together, the characterization of this PANKO-C57
model further indicates that PANDER plays a significant role in promoting the advancement and
worsening of type 2 diabetes and its associated abnormalities during pathological states of
dysregulation.
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APPENDICES

Appendix A: Primary Antibodies Utilized
Table A1. Primary Antibodies and their Respective Catalog Numbers Used in SDS-PAGE in
Chapter 3.

Primary Anitbody Used
IRS-1 (C-20)
p-IRS-1 (Tyr 989)
p-PI3K p85α
Total Akt
p-Akt Thr 308 (244F9)
SREBP-1C (Mature & Precursor) (H-160)
Total ACC (C83B10)
p-ACC (Ser79)
Total AMPKα (23A3)
p-AMPKα (Thr172)
GAPDH (14C10)
Total Glycogen Synthase (15B1)
p-Glycogen Synthase (Ser641)
Total CREB
p-CREB (Ser133)
p-FOXO1 (Thr24)/FoxO3a (Thr32)

Source
Santa Cruz Biotechnologies, Cat. # sc-559
Santa Cruz Biotechnologies, Cat. # sc-17200
Santa Cruz Biotechnologies, Cat. # sc-12929
Cell Signaling Technology, Cat. # 4691
Cell Signaling Technology, Cat. # 4056
Santa Cruz Biotechnologies, Cat. # sc-8984
Cell Signaling Technology, Cat. # 3676
Cell Signaling Technology, Cat. # 3661
Cell Signaling Technology, Cat. # 2603
Cell Signaling Technology, Cat. # 2535
Cell Signaling Technology, Cat. # 2118
Cell Signaling Technology, Cat. # 3886
Cell Signaling Technology, Cat. # 3891
Cell Signaling Technology, Cat. # 4820
Cell Signaling Technology, Cat. # 4276
Cell Signaling Technology, Cat. # 9464
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Appendix B: 4005M Breeding Protocol for PANKO-C57 IACUC Approval
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Appendix C: Experimental 4071 R Protocol IACUC Approval
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